Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 29 of 110 Updated Nov 17, 2026

BPC-157

Body Protection Compound-157 · Bepecin · PL 14736

ANECDOTAL + ANIMAL STUDIES · SYNTHETIC PENTADECAPEPTIDE; CYTOPROTECTIVE

▓ 190 indexed citations across PubMed (161), ClinicalTrials.gov (4), EuropePMC (25).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

190 citations across 5 tiers

Tap any tier to jump to that section of the bibliography.

Background

Gastric pentadecapeptide BPC-157 is a synthetic fifteen amino acid oligopeptide derived from a protein found in human gastric juice. BPC-157 has been studied primarily in laboratory animals. BPC-157 is not approved by any drug regulatory agency for human use, and there is limited data regarding its effectiveness on humans.

→ Wikipedia

Mechanism of action

Promotes angiogenesis via VEGFR2 1; upregulates growth factors 1; modulates NO and dopamine pathways 1; stabilizes gut barrier 1

Researched effects

Tendon/ligament/muscle healing 2; gut mucosal repair 13; angiogenesis 13; reduced GI inflammation 1; wound healing 3

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

250 mcg SC 2x daily near injury (Seeds Vol 1 starting dose, common upper bound 500 mcg per dose); 250 mcg oral 2x daily

→ Seeds WA, Peptide Protocols Vol 1 ch.4 (BPC-157 SC + oral starter); r/Peptides wiki near-injury 2x daily consensus

Known concerns

Limited human trials 1; injection site irritation; theoretical pro-angiogenic/tumor concerns 1

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety.

    Acta orthopaedica Belgica · 2026 — SYSTEMATIC REVIEWS · AUTHORITY 84.5

  2. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.

    HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025 — SYSTEMATIC REVIEWS · AUTHORITY 84.5

  3. BPC 157 for Acute Hamstring Muscle Strain Repair

    2026 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 71.5

  4. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery

    2027 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 68.5

  5. A Clinical Trial to Evaluate the Effects of Peptide Gummies on Markers of Inflammation, Physical Performance, and Recovery

    2025 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 67.5

  6. PCO-02 - Safety and Pharmacokinetics Trial

    2015 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 65.5

  7. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

    Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 — REVIEWS · AUTHORITY 54.5

  8. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    The American journal of sports medicine · 2026 — REVIEWS · AUTHORITY 54.5

  9. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

    International journal of molecular sciences · 2026 — REVIEWS · AUTHORITY 54.5

  10. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Sports medicine (Auckland, N.Z.) · 2026 — REVIEWS · AUTHORITY 54.5

Full citation library

Year distribution

Systematic Reviews

2
  1. 1.

    Vasireddi N, Hahamyan H, Salata MJ, Karns M, et al. · HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025 · PMID 40756949

  2. 2.

    Poolton JT, Minett J, Kazmi A · Acta orthopaedica Belgica · 2026 · PMID 42885452

    or mzyjp23@nottingham.ac.uk Body Protective Compound-157 (BPC-157) is a synthetic pentadecapeptide popular among athletic populations for musculoskeletal injury recovery, despite lacking regulatory approval for human use and evidence being largely limited to animal models. This PRISMA-compliant systematic review, prospectively registered with PROSPERO (CRD420261406325), aimed to evaluate the efficacy and safety of BPC-157 for orthopaedic and regenerative purposes in humans. Electronic databases…

Trial Registrations (ClinicalTrials.gov)

4
  1. 3.

    NCT07437547 · Phase 2 · Recruiting · 2026

    Conditions: Hamstring Muscle Strain, Skeletal Muscle Injury

  2. 4.

    NCT02637284 · Phase 1 · Unknown · 2015

    Conditions: Healthy Volunteers

  3. 5.

    NCT07752381 · NA · Completed · 2025

    Conditions: Musculoskeletal Inflammation, Exercise-Induced Muscle Damage, Post-Exercise Recovery (+1)

  4. 6.

    NCT07803250 · Phase 1 · Not Yet Recruiting · 2027

    Conditions: Rotator Cuff Tear

Reviews

40
  1. 7.

    Józwiak M, Bauer M, Kamysz W, Kleczkowska P · Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 40005999

    BPC 157, known as the "Body Protection Compound", is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory bowel disease, or even CNS disorders. Unlike many other drugs, BPC 157 has a desirable safety profile, since only a few side effects have been reported following its administration. Nevertheless, this compound was temporarily banned by the World…

  2. 8.

    Gwyer D, Wragg NM, Wilson SL · Cell and tissue research · 2019 · PMID 30915550

    There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders. Currently, several therapies are emerging and undergoing trials in animal models; these focus on the manipulation and administration of several growth factors implicated with healing. However, limitations include in vivo instability, reliance on biocompatible and robust carriers and restricted application…

  3. 9.

    Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, et al. · Frontiers in pharmacology · 2021 · PMID 34267654

  4. 10.

    DeFoor MT, Dekker TJ · Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association · 2025 · PMID 39265666

    High-level athletes and bodybuilders are constantly seeking novel therapies to enhance recovery and expedite return from injury-injectable peptides are a new and trending therapy that may be the wave of the future in the realm of regenerative medicine research in treating joint injuries and osteoarthritis. Very early in vivo research on pharmacokinetics indicates the possibility that body protection compound 157 (BPC-157) is at the forefront of therapeutic peptides, with early demonstrations of…

  5. 11.

    Seiwerth S, Rucman R, Turkovic B, Sever M, et al. · Current pharmaceutical design · 2018 · PMID 29998800

    Commonly, the angiogenic growth factors signify healing. However, gastrointestinal ulceration is still poorly understood particularly with respect to a general pharmacological/pathophysiological role of various angiogenic growth factors implemented in growth factors wound healing concept. Thereby, we focused on the stable gastric pentadecapeptide BPC 157, a peptide given always alone vs. standard peptidergic angiogenic growth factors (EGF, FGF, VEGF), and numerous carriers. Further, we reviewed…

  6. 12.

    McGuire FP, Martinez R, Lenz A, Skinner L, et al. · Current reviews in musculoskeletal medicine · 2025 · PMID 40789979

    This scoping review aims to evaluate the molecular mechanisms, therapeutic potential, and safety concerns of Body Protective Compound-157 (BPC-157) in the context of musculoskeletal healing. Given the compound’s increasing availability, popularity, and its regulatory controversies, we sought to assess the breadth and quality of preclinical and clinical data supporting its use in musculoskeletal medicine. BPC-157 is a synthetic pentadecapeptide originally isolated from gastric juice and has demon…

  7. 13.

    Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026 · PMID 41490200

    Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodel…

  8. 14.

    Mayfield CK, Bolia IK, Feingold CL, Lin EH, et al. · The American journal of sports medicine · 2026 · PMID 41476424

    Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides. To evaluate the curre…

  9. 15.

    Sikiric P, Seiwerth S, Brcic L, Blagaic AB, et al. · Inflammopharmacology · 2006 · PMID 17186181

    Gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419, safe in clinical trials for inflammatory bowel disease (PL 10, PLD 116, PLD 14736, Pliva, Croatia)) has a particular cytoprotective/adaptive cytoprotective activity. The cytoprotective/adaptive cytoprotection researches largely neglect that stomach distension could per se jeopardize the mucosal integrity, with constantly stretched mucosa and blood vessels, and sphincters more prone for reflux induction. After absolute alcohol instilla…

  10. 16.

    Vukojevic J, Milavić M, Perović D, Ilić S, et al. · Neural regeneration research · 2022 · PMID 34380875

    We reviewed the pleiotropic beneficial effects of the stable gastric pentadecapeptide BPC 157, three very recent demonstrations that may be essential in the gut-brain and brain-gut axis operation, and therapy application in the central nervous system disorders, in particular. Firstly, given in the reperfusion, BPC 157 counteracted bilateral clamping of the common carotid arteries-induced stroke, sustained brain neuronal damages were resolved in rats as well as disturbed memory, locomotion, and c…

  11. 17.

    Staresinic M, Japjec M, Vranes H, Prtoric A, et al. · Biomedicines · 2022 · PMID 36551977

    First, we review the definitively severed myotendinous junction and recovery by the cytoprotective stable gastric pentadecapeptide BPC 157 therapy, its healing that might combine both transected and detached tendon and transected muscle, ligament and bone injuries, applied alone, as native peptide therapy, effective in rat injury, given intraperitoneally or in drinking water or topically, at the site of injury. As a follow up, we reviewed that with the BPC 157 therapy, its cytoprotective ability…

  12. 18.

    Sikiric P, Kokot A, Kralj T, Zlatar M, et al. · Pharmaceuticals (Basel, Switzerland) · 2023 · PMID 37513963

    Recently, stable gastric pentadecapeptide BPC 157 therapy by activation of collateral pathways counteracted various occlusion/occlusion-like syndromes, vascular, and multiorgan failure, and blood pressure disturbances in rats with permanent major vessel occlusion and similar procedures disabling endothelium function. Thereby, we revealed BPC 157 cytoprotective therapy with strong vascular rescuing capabilities in glaucoma therapy. With these capabilities, BPC 157 therapy can recover glaucomatous…

  13. 19.

    Sikiric P, Seiwerth S, Rucman R, Turkovic B, et al. · Current pharmaceutical design · 2011 · PMID 21548867

    Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, safe in inflammatory bowel disease clinical trials (GEPPPGKPADDAGLV, M.W. 1419, PL 14736) and wound healing, stable in human gastric juice and has no reported toxicity. We focused on BPC 157 as a therapy in peridontitis, esophagus, stomach, duodenum, intestine, liver and pancreas lesions. Particularly, it has a prominent effect on alcohol-lesions (i.e., acute, chronic) and NSAIDs-lesions (interestingly, BPC 157 both prev…

  14. 20.

    Sikiric P, Seiwerth S, Rucman R, Turkovic B, et al. · Current pharmaceutical design · 2013 · PMID 22950504

    Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, proven in clinical trials to be both safe in inflammatory bowel disease (PL-10, PLD-116, PL 14736) and wound healing, stable in human gastric juice, with no toxicity being reported. Recently, we claim that BPC 157 may be used as an antidote against NSAIDs. We focused on BPC 157 beneficial effects on stomach, duodenum, intestine, liver and brain injuries, adjuvant arthritis, pain, hyper/hypothermia, obstructive thrombus f…

  15. 21.

    Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, et al. · Pharmaceuticals (Basel, Switzerland) · 2024 · PMID 38675421

    We highlight the particular aspects of the stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity (not destroyed in human gastric juice, native and stable in human gastric juice, as a cytoprotection mediator holds a response specifically related to preventing or recovering damage as such) and its possible relations with neurotransmitter activity. We attempt to resolve the shortage of the pleiotropic beneficial effects of BPC 157, given the general standard neurotransmitter crite…

  16. 22.

    Seiwerth S, Brcic L, Vuletic LB, Kolenc D, et al. · Current pharmaceutical design · 2014 · PMID 23782145

    This review focuses on the described effects of BPC 157 on blood vessels after different types of damage, and elucidate by investigating different aspects of vascular response to injury (endothelium damage, clotting, thrombosis, vasoconstriction, vasodilatation, vasculoneogenesis and edema formation) especially in connection to the healing processes. In this respect, BPC 157 was concluded to be the most potent angiomodulatory agent, acting through different vasoactive pathways and systems (e.g.…

  17. 23.

    Sikiric P, Seiwerth S, Rucman R, Turkovic B, et al. · Current pharmaceutical design · 2014 · PMID 23755725

    We reviewed stable gastric pentadecapeptide BPC 157-NO-system-relation, its close participation in Moncada's (maintained vascular integrity, platelets control) homeostatic healing response of NO-system to injury. Namely, BPC 157's particular healing effect also affects all events after vascular integrity loss (dependent on circumstances, it reduces either thrombosis (abdominal aorta anastomosis) or bleeding/thrombocytopenia (amputation, heparin, warfarin, aspirin)) and in a series of different i…

  18. 24.

    Sikiric P, Seiwerth S, Skrtic A, Staresinic M, et al. · Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 40573323

    Although approached through many concepts, the pleiotropic healing issue, specifically, maintaining/reestablishing tissue integrity, remains a central challenge in pharmacology, particularly when the process is misdirected or not properly controlled. Robert and Szabo's concept of cytoprotection holds that innate cell (epithelial (Robert), endothelial (Szabo)) integrity and protection/maintenance/reestablishment in the stomach is translated to other organ therapy (cytoprotection → organoprotectio…

  19. 25.

    Sikiric P, Drmic D, Sever M, Klicek R, et al. · Current pharmaceutical design · 2020 · PMID 32329684

    This review is focused on the healing of fistulas and stable gastric pentadecapeptide BPC 157. Assuming that the healing of the various wounds is essential also for the gastrointestinal fistulas healing, the healing effect on fistulas in rats, consistently noted with the stable gastric pentadecapeptide BPC 157, may raise several interesting possibilities. BPC 157 is originally an anti-ulcer agent, native to and stable in human gastric juice (for more than 24 h). Likely, it is a novel mediator of…

  20. 26.

    Park JM, Lee HJ, Sikiric P, Hahm KB · Current pharmaceutical design · 2020 · PMID 32445447

    The stable gastric pentadecapeptide BPC 157 protects stomach cells, maintains gastric integrity against various noxious agents such as alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs), and exerts cytoprotection/ adaptive cytoprotection/organoprotection in other epithelia, that is, skin, liver, pancreas, heart, and brain. Especially BPC 157 counteracts gastric endothelial injury that precedes and induces damage to the gastric epithelium and generalizes "gastric endothelial protection" to pr…

  21. 27.

    Sikiric P, Sever M, Krezic I, Vranes H, et al. · Inflammopharmacology · 2024 · PMID 38980576

    Since the early 1990s, when Robert's and Szabo's cytoprotection concept had already been more than one decade old, but still not implemented in therapy, we suggest the stable gastric pentadecapeptide BPC 157 as the most relevant mediator of the cytoprotection concept. Consequently, it can translate stomach and gastrointestinal mucosal maintenance, epithelium, and endothelium cell protection to the therapy of other tissue healing (organoprotection), easily applicable, as native and stable in huma…

  22. 28.

    Yuan C, Demers A, Silva-Ortiz V, Hasoon JJ, et al. · International journal of molecular sciences · 2026 · PMID 41898733

    Body Protective Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from gastric proteins that has demonstrated notable reparative and anti-inflammatory properties across diverse preclinical models. Experimental evidence reveals that BPC-157 supports angiogenesis, collagen synthesis, fibroblast activity, and modulation of nitric oxide pathways, contributing to enhanced healing of muscle, tendon, ligament, bone, and gastrointestinal tissue. Studies also report reduced inflammatory cyto…

  23. 29.

    Sikiric P, Gojkovic S, Krezic I, Smoday IM, et al. · Pharmaceuticals (Basel, Switzerland) · 2023 · PMID 37242459

    Conceptually, a wide beneficial effect, both peripherally and centrally, might have been essential for the harmony of brain-gut and gut-brain axes' function. Seen from the original viewpoint of the gut peptides' significance and brain relation, the favorable stable gastric pentadecapeptide BPC 157 evidence in the brain-gut and gut-brain axes' function might have been presented as a particular interconnected network. These were the behavioral findings (interaction with main systems, anxiolytic, a…

  24. 30.

    Sikiric P, Seiwerth S, Rucman R, Kolenc D, et al. · Current neuropharmacology · 2016 · PMID 27138887

    Brain-gut interaction involves, among others, peptidergic growth factors which are native in GI tract and have strong antiulcer potency and thus could from periphery beneficially affect CNS-disorders. We focused on the stable gastric pentadecapeptide BPC 157, an antiulcer peptidergic agent, safe in inflammatory bowel disease trials and now in multiple sclerosis trial, native and stable in human gastric juice. Review of our research on BPC 157 in terms of brain-gut axis. BPC 157 may serve as a no…

  25. 31.

    Bajramagic S, Sever M, Rasic F, Staresinic M, et al. · Pharmaceuticals (Basel, Switzerland) · 2024 · PMID 39204186

    By introducing the healing of many distinctive anastomoses by BPC 157 therapy, this review practically deals with the concept of the resection and reconnection of the hollow parts of the gastrointestinal tract as one of the cornerstones of visceral surgery. In principle, the healing of quite distinctive anastomoses itself speaks for applied BPC 157 therapy, in particular, as a way in which the therapy of anastomoses can be successfully approached and carried out. Some of the anastomoses implicat…

  26. 32.

    Sikiric P, Rucman R, Turkovic B, Sever M, et al. · Current pharmaceutical design · 2018 · PMID 29879879

    Years ago, we revealed a novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157, particular anti-ulcer peptide that heals different organs lesions when given as a therapy, native in human gastric juice while maintaining GI-tract mucosal integrity, already tested in trials (ulcerative colitis and now multiple sclerosis). The stomach cytoprotection is the most fundamental concept, stomach cell protection and endothelium protection are largely elaborated, but so far cell, protection…

  27. 33.

    Sikiric P, Seiwerth S, Skrtic A, Staresinic M, et al. · Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 40573261

    In this study, pharmacotherapies of abdominal compartment syndrome (ACS) and intra-abdominal hypertension (IAH) in animal studies were reviewed from the perspective of ACS/IAH as failed cytoprotection issues, as non-specific injuries, and from the point of view of the cytoprotection concept as resolution. Therefore, this review challenges the unresolved theoretical and practical issues of severe multiorgan failure, acknowledged significance in clinics, and resolving outcomes (i.e., open abdomen)…

  28. 34.

    Sikiric P, Hahm KB, Blagaic AB, Tvrdeic A, et al. · Gut and liver · 2020 · PMID 31158953

    We reviewed again the significance of the stable gastric pentadecapeptide BPC 157 as a likely mediator of Robert's stomach cytoprotection/adaptive cytoprotection and organoprotection and as novel mediator of Selye's stress coping response to reestablish homeostasis. Specific points of BPC 157 therapy and the original concept of Robert's cytoprotection/adaptive cytoprotection/organoprotection are discussed, including the beneficial effects of BPC 157. First, BPC 157 protects stomach cells and mai…

  29. 35.

    Sikiric P, Seiwerth S, Rucman R, Turkovic B, et al. · Current medicinal chemistry · 2012 · PMID 22300085

    Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protect…

  30. 36.

    Sikiric P, Udovicic M, Barisic I, Balenovic D, et al. · Biomedicines · 2022 · PMID 36359218

    In heart disturbances, stable gastric pentadecapeptide BPC 157 especial therapy effects combine the therapy of myocardial infarction, heart failure, pulmonary hypertension arrhythmias, and thrombosis prevention and reversal. The shared therapy effect occurred as part of its even larger cytoprotection (cardioprotection) therapy effect (direct epithelial cell protection; direct endothelium cell protection) that BPC 157 exerts as a novel cytoprotection mediator, which is native and stable in human…

  31. 37.

    Sikiric P, Seiwerth S, Brcic L, Sever M, et al. · Current pharmaceutical design · 2010 · PMID 20166993

    The significance of cytoprotection and adaptive cytoprotection and the peptides importance remained to be not completely determined. BPC 157 is an anti-ulcer peptidergic agent, proven in clinical trials to be both safe in inflammatory bowel disease (PL-10, PLD-116, PL 14736) and wound healing, and stable in human gastric juice, with no toxicity being reported. It has a prominent effect on alcohol- lesions (i.e., induced acutely and chronically) and non-steroidal anti-inflammatory drugs-lesions (…

  32. 38.

    Sikiric P, Boban Blagaic A, Krezic I, Zizek H, et al. · Pharmaceuticals (Basel, Switzerland) · 2023 · PMID 38139825

    We reviewed gastric ulcer healing by dopamine considering several distinctive duodenal key points. Selye and Szabo describe the cysteamine-induced duodenal ulcer in rats as a duodenal stress ulcer in patients. Szabo's cysteamine duodenal ulcer as the dopamine duodenal healing and cysteamine as a dopamine antagonist signifies the dopamine agonists anti-ulcer effect and dopamine antagonists ulcerogenic effect. From these viewpoints, we focused on dopamine and gastric ulcer healing. We mentioned an…

  33. 39.

    Sikiric P, Seiwerth S, Rucman R, Drmic D, et al. · Current pharmaceutical design · 2017 · PMID 28228068

    Selye's syndrome produced by diverse nocuous agents and "response to damage as such" means Selye's stress triad in stress coping response to reestablish homeostasis. Logically, from the gastrointestinal tract viewpoint, such organoprotective/healing response implies the angiogenic growth factors that commonly signify the healing. Thereby, the gastric pentadecapeptide BPC 157-organoprotection (huge range of beneficial effects) signifies the Selye's stress concept/stress coping response implemente…

  34. 40.

    Sikirić P, Petek M, Rucman R, Seiwerth S, et al. · Journal of physiology, Paris · 1993 · PMID 8298609

    The possibility that the stomach, affected by general stress, might initiate a counter-response has not until recently been considered in theories of stress. We suggest that the stomach, as the most sensitive part of the gastrointestinal tract and the largest neuroendocrine organ in the body, is crucial for the initiation of a full stress response against all noxious stress pathology. The end result would be a strong protection of all organs invaded by 'stress'. Consistent with this assumption,…

  35. 41.

    Masnec S, Kokot A, Kralj T, Zlatar M, et al. · Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 41471311

    To better address the challenge of corneal ulcer healing, with already available standard agents, and those recently introduced, such as stable gastric pentadecapeptide BPC 157, we introduced a novel conceptual framework-the "triad" of corneal ulcer healing↔corneal neovascularization↔intraocular pressure-and extended it to avascular tissues such as tendon. Within this framework, cytoprotection serves as the unifying principle, underscoring that therapeutic effects are not isolated but interconne…

  36. 42.

    Szabo S, Yoshida M, Filakovszky J, Juhasz G · Current pharmaceutical design · 2017 · PMID 28641541

    The first scientific publication on 'general adaption syndrome', or as we know today 'biologic stress' has been published in Nature in 1936 by the 29-year old Hans Selye. His results in that short publication that contained no references or illustrations, were based on experiments in rats that were exposed to severe insults/ stressors, but his idea about a 'nonspecific bodily response' originated from his observations of sick patients whom he had seen as a medical student and young clinician. Au…

  37. 43.

    Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026 · PMID 41966639

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside of regulatory oversight. Our objecti…

  38. 44.

    Sever M, Zenko Sever A, Klicek R, Kralj L, et al. · Pharmaceuticals (Basel, Switzerland) · 2026 · PMID 42943255

    Cytoprotection provides a conceptual framework for the preservation and restoration of tissue integrity under conditions of noxious injury. In liver disease, however, effective protection may require more than direct limitation of hepatocellular damage, encompassing endothelial function, microcirculation, vascular homeostasis, oxidative stress, inflammation, fibrosis, and portal hemodynamics. This review examines possibilities for cytoprotective liver therapy, with particular emphasis on stable…

  39. 45.

    Demirtaş H · International journal of molecular sciences · 2026 · PMID 42794771

    Ischemia-reperfusion injury (IRI) is a clinically important consequence of blood-flow restoration after ischemia and contributes to tissue damage across multiple organ systems. This critical review evaluates the preclinical evidence for BPC 157 in rodent IRI and related reperfusion-associated vascular injury models, with particular attention to oxidative stress, endothelial and nitric oxide (NO)-related responses, inflammation, apoptosis, angiogenic signaling, and tissue injury. Searches were pe…

  40. 46.

    Mateescu DM, Gavrilescu DM, Constantinescu FE, Oancea C, et al. · Pharmaceutics · 2026 · PMID 42198317

Research Articles

134
  1. 47.

    Lee E, Padgett B · Alternative therapies in health and medicine · 2021 · PMID 34324435

    Knee pain, a common complaint in primary care, has many causes, the most common of which is osteoarthritis (OA). Other common causes are meniscus tears, tendinosis, ligament tears or sprains, rheumatoid arthritis, lupus and septic arthritis. Also, referred pain from hip joint pathology like slipped capital femoral epiphysis can result in knee pain.1 The use of peptides BPC157 and thymosin-beta-4 (TB4) has not been studied in the treatment of knee pain. A retrospective study was done at the Insti…

  2. 48.

    Chang CH, Tsai WC, Lin MS, Hsu YH, et al. · Journal of applied physiology (Bethesda, Md. : 1985) · 2011 · PMID 21030672

    Pentadecapeptide BPC 157, composed of 15 amino acids, is a partial sequence of body protection compound (BPC) that is discovered in and isolated from human gastric juice. Experimentally it has been demonstrated to accelerate the healing of many different wounds, including transected rat Achilles tendon. This study was designed to investigate the potential mechanism of BPC 157 to enhance healing of injured tendon. The outgrowth of tendon fibroblasts from tendon explants cultured with or without B…

  3. 49.

    Lee E, Burgess K · Alternative therapies in health and medicine · 2025 · PMID 40131143

    For years, the peptide Body Protection Compound 157 (BPC-157) has been used to treat partial muscle or tendon tears. Few studies on humans have been published, with none on the intravenous use of BPC-157 in humans. This IRB-approved study was conducted to assess whether intravenous BPC-157 is safe in humans. Baseline blood work and vital signs were obtained from 2 participants before and after each infusion. On day 1, 10 mg of BPC-157 in 250 cc of normal saline was infused over one hour. On day…

  4. 50.

    Cerovecki T, Bojanic I, Brcic L, Radic B, et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2010 · PMID 20225319

    We improved medial collateral ligament (MCL) healing throughout 90 days after surgical transection. We introduced intraperitoneal, per-oral (in drinking water) and topical (thin cream layer) peptide therapy always given alone, without a carrier. Previously, as an effective peptide therapy, stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, an anti-ulcer peptide effective in inflammatory bowel disease therapy (PL 14736)) particularly improved healing of transected tendon and muscle and wou…

  5. 51.

    Lee E, Walker C, Ayadi B · Alternative therapies in health and medicine · 2024 · PMID 39325560

    Moderate to severe interstitial cystitis (also known as bladder pain syndrome) is a disabling disease with no effective treatment. Although pentosan polysulfate is an approved treatment for interstitial cystitis, some patients on this medication experience treatment failure after one year, and its long-term use has been linked to pigmentary maculopathy. The peptide Body Protective Compound 157 (BPC-157) is a possible treatment for interstitial cystitis but is currently not approved by the US Foo…

  6. 52.

    Ilic S, Drmic D, Zarkovic K, Kolenc D, et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2010 · PMID 20436226

    We focused on stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419, an anti-ulcer peptide efficient in inflammatory bowel disease trials (PL 14736), no toxicity reported) because of its hepatoprotective effects. We investigate a particular aspect of the sudden onset of encephalopathy with extreme paracetamol overdose (5 g/kg intraperitoneally) so far not reported: rapidly induced progressive hepatic encephalopathy with generalized convulsions in rats. BPC 157 therapy (10 microg, 10…

  7. 53.

    Sikiric P, Skrtic A, Gojkovic S, Krezic I, et al. · World journal of gastroenterology · 2022 · PMID 35125818

    The stable gastric pentadecapeptide BPC 157 counteracts various venous occlusion-induced syndromes. Summarized are all these arguments, in the Robert's cytoprotection concept, to substantiate the resolution of different major vessel occlusion disturbances, in particular ischemia-reperfusion injury following the Pringle maneuver and Budd-Chiari syndrome, which was obtained by BPC 157 therapy. Conceptually, there is a new point, namely, endothelium maintenance to epithelium maintenance (the recrui…

  8. 54.

    Sikiric P, Gojkovic S, Knezevic M, Tepes M, et al. · Current medicinal chemistry · 2023 · PMID 36200148

  9. 55.

    Sikiric P, Seiwerth S, Skrtic A, Staresinic M, et al. · Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 41155565

    The healing issue is a central, not completely understood, problem in pharmacology, approached by many concepts. One of the most well-known is Robert's and Szabo's concept of cytoprotection, which holds innate cell (epithelial (Robert), endothelial (Szabo)) integrity, protection/maintenance/reestablishing in the stomach to be translated to other organ therapy (cytoprotection→organoprotection) via cytoprotection agent's effect. Thereby, we defend stable gastric pentadecapeptide BPC 157 therapy, e…

  10. 56.

    Seveljević-Jaran D, Cuzić S, Dominis-Kramarić M, Glojnarić I, et al. · Skin pharmacology and physiology · 2006 · PMID 16785777

    PL 14736 is a synthetic peptide, originally isolated from human gastric juice, that has anti-inflammatory and tissue-protective actions in experimental models of gastrointestinal inflammation. To investigate its possible benefit in poorly healing skin wounds, the effects of the topical application of PL 14736 in a gel formulation have been studied on full-thickness excisional wounds in rats, either healthy or made hyperglycemic by alloxan (175 mg/kg s.c.) 5 days previously. The effects of becapl…

  11. 57.

    Zemba Cilic A, Zemba M, Cilic M, Balenovic I, et al. · Behavioural brain research · 2021 · PMID 32956773

    In the suited rat-models, we focused on the stable pentadecapeptide BPC 157, L-NAME, NOS-inhibitor, and L-arginine, NOS-substrate, relation, the effect on schizophrenia-like symptoms. Medication (mg/kg intraperitoneally) was L-NAME (5), L-arginine (100), BPC 157 (0.01), given alone and/or together, at 5 min before the challenge for the acutely disturbed motor activity (dopamine-indirect/direct agonists (amphetamine (3.0), apomorphine (2.5)), NMDA-receptor non-competitive antagonist (MK-801 (0.2)…

  12. 58.

    Seiwerth S, Sikiric P, Grabarevic Z, Zoricic I, et al. · Journal of physiology, Paris · 1997 · PMID 9403790

    The 15 amino acid agent BPC 157, showing a wide range of organoprotective action in different experimental models, was used in our experiments in order to establish its influence on different elements connected with the healing process. Elements thought to be of greatest importance in the process of healing are formation of granulation tissue, angiogenesis and production of collagen. In our work we tested the influence of BPC 157 on: granulation tissue and collagen formation, on angiogenesis as…

  13. 59.

    Whitehouse M · Inflammopharmacology · 2025 · PMID 40759852

    This article discusses the lengthy review by Pedrag Sikiric and twenty one (21) co-authors in Inflammopharmacology (2024) 32:3119-3161.

  14. 60.

    Jung YH, Kim H, Kim H, Kim E, et al. · Journal of dental anesthesia and pain medicine · 2022 · PMID 35449779

    The pentadecapeptide BPC-157 has been shown to have anti-inflammatory and wound healing effects on multiple target tissues and organs. Peptides have potent anti-inflammatory effects on periodontal tissues in rats with periodontitis. Few studies have investigated the effect of BPC-157 on pain after dental procedures or oral surgeries. The purpose of the present study was to investigate the antinociceptive effects of BPC-157 on postoperative incisional pain in rats. Sprague-Dawley rats were random…

  15. 61.

    Deek SA · Medical hypotheses · 2021 · PMID 34798584

    The emergence of coronavirus disease (COVID-19) in China at the end of 2019 has caused a large global outbreak. COVID-19 is largely seen as a thrombotic and vascular disease targeting endothelial cells (ECs) throughout the body that can provoke the breakdown of central vascular functions. This explains the complications and multi-organ failure seen in COVID-19 patients including acute respiratory distress syndrome, cardiovascular complications, liver damage, and neurological damage. Acknowledgin…

  16. 62.

    Baric M, Sever AZ, Vuletic LB, Rasic Z, et al. · Life sciences · 2016 · PMID 26872976

    Rectovaginal fistula is a devastating condition providing more than 99% of patients for surgical treatment. We hypothesized that rectovaginal fistula may be healed by therapy with stable gastric pentadecapeptide BPC 157, in consistence with its initial clinical application and effect on external fistulas. BPC 157 (10μg/kg or 10ng/kg) was given perorally, in drinking water (0.16μg/ml or 0.16ng/ml, 12ml/rat/day) till sacrifice, or alternatively, intraperitoneally, first application at 30min after…

  17. 63.

    Boban Blagaic A, Blagaic V, Mirt M, Jelovac N, et al. · European journal of pharmacology · 2005 · PMID 15840402

    Serotonin syndrome commonly follows irreversible monoamine oxidase (MAO)-inhibition and subsequent serotonin (5-HT) substrate (in rats with fore paw treading, hind limbs abduction, wet dog shake, hypothermia followed by hyperthermia). A stable gastric pentadecapeptide BPC 157 with very safe profile (inflammatory bowel disease clinical phase II, PL-10, PLD-116, PL-14736, Pliva) reduced the duration of immobility to a greater extent than imipramine, and, given peripherally, has region specific inf…

  18. 64.
  19. 65.

    Vukojević J, Vrdoljak B, Malekinušić D, Siroglavić M, et al. · Brain and behavior · 2020 · PMID 32558293

    We focused on the, yet undescribed, therapy effect of the stable gastric pentadecapeptide BPC 157 in hippocampal ischemia/reperfusion injuries, after bilateral clamping of the common carotid arteries in rats. The background is the proven therapy effect of BPC 157 in ischemia/reperfusion injuries in different tissues. Furthermore, there is the subsequent oxidative stress counteraction, particularly when given during reperfusion. The recovering effect it has on occluded vessels, results with activ…

  20. 66.

    Zivanovic-Posilovic G, Balenovic D, Barisic I, Strinic D, et al. · European journal of pharmacology · 2016 · PMID 27815173

    Bupivacaine toxicity following accidental overdose still lacks therapeutic solution. However, there are major arguments for testing BPC 157 against bupivacaine toxicity in vivo in rats, in particular, and then finally, in vitro. These are: the lack of any known BPC 157 toxicity, a lifesaving effect via the mitigation of arrhythmias in rats underwent hyperkalemia or digitalis toxicity, the elimination of hyperkalemia and arrhythmias in rats underwent succinylcholine toxicity and finally, the redu…

  21. 67.

    Kralj T, Kokot A, Zlatar M, Masnec S, et al. · Biomedicines · 2021 · PMID 35052769

    Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats. If not upgraded, one episcleral vein is regularly unable to acquire and take over the whole function, and glaucoma-like features persist. Recently, the rapid upgrading of the collateral pathways by a stable gastric pentadecapeptide BPC 157 has cured many severe syndromes induced by permanent occlusion of major vessels, veins and/or arteries, peripherally and c…

  22. 68.

    Tepes M, Krezic I, Vranes H, Smoday IM, et al. · Pharmaceuticals (Basel, Switzerland) · 2023 · PMID 38004420

    Given in reperfusion, the use of stable gastric pentadecapeptide BPC 157 is an effective therapy in rats. It strongly counteracted, as a whole, decompression/reperfusion-induced occlusion/occlusion-like syndrome following the worst circumstances of acute abdominal compartment and intra-abdominal hypertension, grade III and grade IV, as well as compression/ischemia-occlusion/occlusion-like syndrome. Before decompression (calvariectomy, laparotomy), rats had long-lasting severe intra-abdominal hyp…

  23. 69.

    Barisic I, Balenovic D, Udovicic M, Bardak D, et al. · Biomedicines · 2022 · PMID 35203478

    We revealed that the stable gastric pentadecapeptide BPC 157, a useful peptide therapy against isoprenaline myocardial infarction, as well as against isoprenaline myocardial reinfarction, may follow the counteraction of the recently described occlusion-like syndrome, induced peripherally and centrally, which was described for the first time in isoprenaline-treated rats. BPC 157 (10 ng/kg, 10 µg/kg i.p.), L-NAME (5 mg/kg i.p.), and L-arginine (200 mg/kg i.p.) were given alone or together at (i) 3…

  24. 70.

    Grubisic MM, Strbe S, Barisic I, Balenovic D, et al. · Current neuropharmacology · 2025 · PMID 39865815

    The article has been withdrawn at the author's request from the website of the journal Current Neuropharmacology. Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere…

  25. 71.

    Matek D, Matek I, Staresinic E, Japjec M, et al. · Pharmaceutics · 2025 · PMID 39861766

    This is a novel rat study using native peptide therapy, focused on reversing quadriceps muscle-to-bone detachment to reattachment and stable gastric pentadecapeptide BPC 157 per-oral therapy for shared muscle healing and function restoration. Pharmacotherapy recovering various muscle, tendon, ligament, and bone lesions, and severed junctions (i.e., myotendinous junction), per-oral in particular (BPC 157/kg/day 10 µg, 10 ng), provides muscle-to-bone reattachment after quadriceps muscle detachment…

  26. 72.

    Stupnisek M, Franjic S, Drmic D, Hrelec M, et al. · Thrombosis research · 2012 · PMID 21840572

    Recently, in rat abdominal aorta terminoterminal-anastomosis the stable gastric pentadecapeptide BPC 157 prevents obstructive thrombus formation and rapidly destroys already formed obstructive thrombus. Also, BPC 157 wound healing may signify the clot as conductive matrix or "scaffold" to speed up wound healing process, and decrease bleeding. Here, in rats, BPC 157 (10 μg/kg, 10 ng/kg) improved always reduced bleeding time and amount of bleeding after (tail) amputation only, heparin (250 mg/kg,…

  27. 73.

    Kolovrat M, Gojkovic S, Krezic I, Malekinusic D, et al. · World journal of hepatology · 2020 · PMID 32547687

    The Pringle maneuver [portal triad obstruction(PTO)] provides huge disturbances during ischemia and even more thereafter in reperfusion. Contrarily, a possible solution may be stable gastric pentadecapeptide BPC 157, with already documented beneficial effects in ischemia/reperfusion conditions. Recently, BPC 157, as a cytoprotective agent, successfully resolved vessel occlusions in rats (ischemic colitis; deep vein thrombosis, superior anterior pancreaticoduodenal vein; bile duct cirrhosis) thro…

  28. 74.

    Grgic T, Grgic D, Drmic D, Sever AZ, et al. · European journal of pharmacology · 2016 · PMID 26875638

    To establish the effects of BPC 157 on the healing of rat colovesical fistulas, Wistar Albino male rats were randomly assigned to different groups. BPC 157, a stable gastric pentadecapeptide, has been used in clinical applications-specifically, in ulcerative colitis-and was successful in treating both external and internal fistulas. BPC 157 was provided daily, perorally, in drinking water (10µg/kg, 12ml/rat/day) until sacrifice or, alternatively, 10µg/kg or 10ng/kg intraperitoneally, with the fi…

  29. 75.

    Duplancic B, Stambolija V, Holjevac J, Zemba M, et al. · European journal of pharmacology · 2014 · PMID 24486708

    Anesthetized mice or rats received intravenously 6%, 10%, 20%, 40%, 60%, 80%, and 90% dextran and/or white egg (1ml/rat or 0.15ml/mouse) into their tails. Medication (/kg b.w., 5ml/kg) was given intraperitoneally (BPC 157 10µg, 1µg, 10ng, and 10pg/kg, chloropyramine 20mg/kg, and cimetidine 10mg/kg intraperitoneally, alone or in combination while controls received an equivolume of saline), immediately after challenge or, alternatively, at 5min after or 24 or 48h before challenge. The effect was a…

  30. 76.

    Stambolija V, Stambolija TP, Holjevac JK, Murselovic T, et al. · European journal of pharmacology · 2016 · PMID 27060013

    After the demonstration of its life-saving effect in severe hyperkalemia and the recovery of skeletal muscle after injury, pentadecapeptide BPC 157 has been shown to attenuate the local paralytic effect induced by succinylcholine, in addition to systemic muscle disability (and consequent muscle damage). Hyperkalemia, arrhythmias and a rise in serum enzyme values, were counteracted in rats. Assessments were made at 3 and 30min and 1, 3, 5, and 7 days after succinylcholine administration (1.0mg/kg…

  31. 77.

    Pevec D, Novinscak T, Brcic L, Sipos K, et al. · Medical science monitor : international medical journal of experimental and clinical research · 2010 · PMID 20190676

    The effect of systemic and local peptide treatment effective in muscle contusion and then on counteraction of corticosteroid-induced impairment was tested. The pentadecapeptide BPC 157, given without a carrier, improved the healing of transected quadriceps muscle. It also improved muscle healing in rats with muscle crush injury when applied systemically or locally. Importantly, it counteracted corticosteroid-impairment in tendon to bone healing. Thus BPC 157 is proposed as an effective treatment…

  32. 78.

    Vuksic T, Zoricic I, Brcic L, Sever M, et al. · Surgery today · 2007 · PMID 17713731

    Gastric pentadecapeptide BPC 157 (BPC 157), which has been shown to be safe in clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia), may be able to cure intestinal anastomosis dehiscence. This antiulcer peptide shows no toxicity, is limit test negative, and a lethal dose is not achieved. It is stable in human gastric juice. In comparison with other standard treatments it is more effective for ulcers and various wounds, and can be used without a carrier needed…

  33. 79.

    Tkalcević VI, Cuzić S, Brajsa K, Mildner B, et al. · European journal of pharmacology · 2007 · PMID 17628536

    Apart from becaplermin (recombinant human platelet-derived growth factor homodimer of B chains, PDGF-BB), for the treatment of lower extremity diabetic ulcers, few agents are available for pharmacological stimulation of wound healing. We have compared the mechanism of action of the potential wound healing agent, PL 14736 (G E P P P G K P A D D A G L V), with that of PDGF-BB on granulation tissue formation following sponge implantation in the normoglycemic rat and in healing full-thickness excisi…

  34. 80.

    Smoday IM, Krezic I, Kalogjera L, Vukovic V, et al. · Pharmaceuticals (Basel, Switzerland) · 2023 · PMID 37895979

    After inferior caval vein embolization therapy, post-embolization syndrome (sodium laurate 10 mg/kg, 0.1 mL into rat inferior caval vein, assessment at 15, 30, 60 min, prime lung lesions, thromboemboli occluding lung vessels), as a severe occlusion/occlusion-like syndrome, might be resolved as a whole by stable gastric pentadecapeptide BPC 157 therapy. At 5 min after laurate injection, stable gastric pentadecapeptide BPC 157 was implemented as therapy (10 µg/kg, 10 ng/kg intraperitoneally or int…

  35. 81.

    Zemba Cilic A, Zemba M, Cilic M, Strbe S, et al. · Biomedicines · 2022 · PMID 35884767

    We attempted throughout the NO-system to achieve the particular counteraction of the ketamine-induced resembling "negative-like" schizophrenia symptoms in rats using pentadecapeptide BPC 157, and NO-agents, NG-nitro-L-arginine methylester (L-NAME), and/or L-arginine, triple application. This might be the find out the NO-system organized therapy (i.e., simultaneously implied NO-system blockade (L-NAME) vs. NO-system over-stimulation (L-arginine) vs. NO-system immobilization (L-NAME+L-arginine)).…

  36. 82.

    Vukusic D, Zenko Sever A, Sever M, Drmic D, et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2024 · PMID 38583442

    Using duodenocolic fistula in rats, this study attempts to highlight the particular cytoprotection aspects of the healing of fistulas and therapy potential of the stable gastric pentadecapeptide BPC 157, a cytoprotection mediator (i.e. upgrading minor vessels to induce healing at both fistula's sides). Upon duodenocolic fistula creation (two 'perforated' lesions put together) (assessed at 3, 6, 9, 12, and 15 min), BPC 157, given locally at the fistula, or intragastrically (10 μg/kg, 10 ng/kg), r…

  37. 83.

    Gojkovic S, Krezic I, Vranes H, Zizek H, et al. · Biomedicines · 2021 · PMID 34203464

    We show the complex syndrome of the occluded superior sagittal sinus, brain swelling and lesions and multiple peripheral organs lesions in rat. Recovery goes centrally and peripherally, with the stable gastric pentadecapeptide BPC 157, which alleviated peripheral vascular occlusion disturbances, rapidly activating alternative bypassing pathways. Assessments were gross recording, venography, ECG, pressure, microscopy, biochemistry. The increased pressure in the superior sagittal sinus, portal and…

  38. 84.

    Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, et al. · Acta pharmacologica Sinica · 2002 · PMID 11978191

    To investigate the effect of pentadecapeptide BPC 157 on chronic exposure to amphetamine in rats, particularly the changes commonly referred in chronic amphetamine studies as tolerance (lesser grade of stereotyped behavior, without increased excitability) and reverse tolerance (ie, prominent stereotyped behavior and heightened startle response upon late amphetamine challenges). After initial application (initial single dose-regimen), amphetamine (10 mg/kg,ip) was given once daily till d 5 (conti…

  39. 85.

    Kalogjera L, Krezic I, Smoday IM, Vranes H, et al. · World journal of gastroenterology · 2023 · PMID 37545637

    Using rat stomach perforation as a prototypic direct lesion applied in cytoprotection research, we focused on the first demonstration of the severe occlusion/ occlusion-like syndrome induced by stomach perforation. The revealed stomach-induced occlusion/occlusion-like syndrome corresponds to the previously described occlusion/occlusion-like syndromes in rats suffering multicausal pathology and shared severe vascular and multiorgan failure. This general point was particularly reviewed. As in all…

  40. 86.

    Demirtaş H, Özer A, Yıldırım AK, Dursun AD, et al. · Medicina (Kaunas, Lithuania) · 2025 · PMID 40005408

  41. 87.

    Sikiric P, Jelovac N, Jelovac-Gjeldum A, Dodig G, et al. · Acta pharmacologica Sinica · 2001 · PMID 11742568

    To study anxiolytic effect of a gastric pentadecapeptide, BPC-157. In shock probe/burying test, pentadecapeptide BPC-157 (10 microg/kg, 10 ng/kg, ip), diazepam (0.075, 0.0375 mg/kg, ip), and an equivolume of saline (5 mL/kg, ip) were given at 30 min prior test. In light/dark test, the same dosage of diazepam, BPC-157, and saline were given at 45 min prior procedure. Shock probe/burying test: rats treated with either diazepam or pentadecapeptide BPC-157 were much less afraid after the shock: almo…

  42. 88.

    Bilic M, Bumber Z, Blagaic AB, Batelja L, et al. · Burns : journal of the International Society for Burn Injuries · 2005 · PMID 15774286

    The stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV; mol. wt. 1419), which is at present in phase II clinical trials for the treatment of inflammatory bowel disease, has been shown to counteract healing impairment by systemic corticosteroids in burned mice, both in vivo and in vitro, in the absence of carrier or protease inhibitor. Because of the particular healing problems associated with laser use, we have now studied the effect of pentadecapeptide BPC 157 on CO(2) laser injuries (Sha…

  43. 89.

    Tepes M, Gojkovic S, Krezic I, Zizek H, et al. · Frontiers in pharmacology · 2021 · PMID 34966273

    Recently, the stable gastric pentadecapeptide BPC 157 was shown to counteract major vessel occlusion syndromes, i.e., peripheral and/or central occlusion, while activating particular collateral pathways. We induced abdominal compartment syndrome (intra-abdominal pressure in thiopental-anesthetized rats at 25 mmHg (60 min), 30 mmHg (30 min), 40 mmHg (30 min), and 50 mmHg (15 min) and in esketamine-anesthetized rats (25 mmHg for 120 min)) as a model of multiple occlusion syndrome. By improving the…

  44. 90.

    Cesarec V, Becejac T, Misic M, Djakovic Z, et al. · European journal of pharmacology · 2013 · PMID 23220707

    Esophagocutaneous fistulas are a failure of the NO-system, due to NO-synthase blockage by the NOS-blocker L-NAME consequently counteracted by l-arginine and gastric pentadecapeptide BPC 157 (l-arginine <BPC 157), precipitating a therapeutic benefit. Previously, there was an established BPC 157-NO-system interaction. BPC 157 GEPPPGKPADDAGLV, MW 1419 (LD1 not achieved), is a safe and stable anti-ulcer peptide, successful in inflammatory bowel disease trials, counteracting esophagitis, sphincter fa…

  45. 91.

    Zlatar M, Kokot A, Vuletic LB, Masnec S, et al. · Frontiers in pharmacology · 2021 · PMID 34177567

    Providing NO-system importance, we suggest that one single application of the NOS-blocker L-NAME may induce retinal ischemia in rats, and that the stable pentadecapeptide BPC 157 may be the therapy, since it may interact with the NO-system and may counteract various adverse effects of L-NAME application. A rat retinal ischemia study was conducted throughout 4 weeks, including fundoscopy, behavior presentation, tonometry, and histology assessment. Retrobulbar L-NAME application (5 mg/kg; 0.5 mg/0…

  46. 92.

    Premuzic Mestrovic I, Smoday IM, Kalogjera L, Krezic I, et al. · Pharmaceuticals (Basel, Switzerland) · 2023 · PMID 37513889

    We focused on the first demonstration that antiarrhythmics, particularly class II and class III antiarrhythmic and beta-blocker sotalol can induce severe occlusion/occlusion-like syndrome in rats. In this syndrome, as in similar syndromes with permanent occlusion of major vessels, peripheral and central, and other similar noxious procedures that severely disable endothelium function, the stable gastric pentadecapeptide BPC 157-collateral pathways activation, was a resolving therapy. After a high…

  47. 93.

    Chang CH, Tsai WC, Hsu YH, Pang JH · Molecules (Basel, Switzerland) · 2014 · PMID 25415472

    BPC 157, a pentadecapeptide derived from human gastric juice, has been demonstrated to promote the healing of different tissues, including skin, muscle, bone, ligament and tendon in many animal studies. However, the underlying mechanism has not been fully clarified. The present study aimed to explore the effect of BPC 157 on tendon fibroblasts isolated from Achilles tendon of male Sprague-Dawley rat. From the result of cDNA microarray analysis, growth hormone receptor was revealed as one of the…

  48. 94.

    Hsieh MJ, Liu HT, Wang CN, Huang HY, et al. · Journal of molecular medicine (Berlin, Germany) · 2017 · PMID 27847966

    BPC 157, a pentadecapeptide with extensive healing effects, has recently been suggested to contribute to angiogenesis. However, the underlying mechanism is not yet clear. The present study aimed to explore the potential therapeutic effect and pro-angiogenic mechanism of BPC 157. As demonstrated by the chick chorioallantoic membrane (CAM) assay and endothelial tube formation assay, BPC 157 could increase the vessel density both in vivo and in vitro, respectively. BPC 157 could also accelerate the…

  49. 95.

    Hsieh MJ, Lee CH, Chueh HY, Chang GJ, et al. · Scientific reports · 2020 · PMID 33051481

    BPC 157-activated endothelial nitric oxide synthase (eNOS) is associated with tissue repair and angiogenesis as reported in previous studies. However, how BPC 157 regulates the vasomotor tone and intracellular Src-Caveolin-1 (Cav-1)-eNOS signaling is not yet clear. The present study demonstrated a concentration-dependent vasodilation effect of BPC 157 in isolated rat aorta. Attenuation of this vasodilation effect in the absence of endothelium suggested an endothelium-dependent vasodilation effec…

  50. 96.

    Klicek R, Kolenc D, Suran J, Drmic D, et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2013 · PMID 24304574

    Stable gastric pentadecapeptide BPC 157 was suggested to link inflammatory bowel disease and multiple sclerosis, and thereby, shown to equally counteract the models of both of those diseases. For colitis, cysteamine (400 mg/kg intrarectally (1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used. BPC 157 (10 μg/kg, 10 ng/kg) was applied either intraperitoneally once time daily (first application immediately after surgery, last at 24 hours before sacrifice) or per-ora…

  51. 97.

    Sikiric P, Seiwerth S, Grabarevic Z, Petek M, et al. · Life sciences · 1994 · PMID 7904712

    The protection of stomach and duodenum in conjecture with anti-inflammatory effect was demonstrated for a novel 15 amino acid peptide, coded BPC 157, a fragment of the recently discovered gastric juice peptide BPC. BPC 157 (i.p./i.g.) was investigated in rats in comparison with several reference standards in three experimental ulcer models (48 h-restraint stress, subcutaneous cysteamine, intragastrical 96% ethanol ulcer tests) (pre-/co-/post-treatment). Only BPC 157 regimens were consistently ef…

  52. 98.

    Keremi B, Lohinai Z, Komora P, Duhaj S, et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2009 · PMID 20388954

    The pentadecapeptide BPC 157 has been shown to have anti-inflammatory and wound healing effects on multiple target tissues and organs. The purpose of the present study was to investigate the effect of BPC 157 on inflammation and bone resorption in experimental periodontitis in rats. First the acute effect of BPC was tested on gingival blood flow by laser doppler flowmetry. Then periodontitis was produced by a silk ligature placed around the lower left first molar. Rats were treated with BPC 157…

  53. 99.

    Prkacin I, Separovic J, Aralicia G, Perovic D, et al. · Journal of physiology, Paris · 2001 · PMID 11595456

    Liver lesions and portal hypertension in rats, following chronic alcohol administration, are a particular target for therapy. Portal hypertension (mm Hg) assessed directly into the portal vein, and liver lesions induced by 7.28 g/kg b.w. of alcohol given in drinking water for 3 months, were counteracted by a stable gastric pentadecapeptide BPC 157, GEPPPGKPADDAGLV, M.W. 1419, known to have a beneficial effect in a variety of models of gastrointestinal or liver lesions (10 microg or 10 ng/kg b.w.…

  54. 100.

    Huang BS, Huang SC, Chen FH, Chang Y, et al. · Life sciences · 2022 · PMID 36228773

    Radiation-induced liver disease (RILD) is the major complication for cancer patients after radiation therapy. We investigated the protective effects of BPC 157 peptide in reducing RILD. Mice were irradiated with a single dose of 12 Gy to induce acute liver injury with or without oral BPC 157. Plasma levels of AST and ALT were determined. In vitro rat liver clone 9 cells and in vivo liver tissues were harvested for MTT assay, TUNEL assay, lipid staining, polypoid cell counts, Western blotting of…

  55. 101.

    Wu H, Wei M, Li N, Lu Q, et al. · Drug design, development and therapy · 2020 · PMID 33376304

    Although Clopidogrel is safe in healthy volunteers, it can induce recurrence of gastric ulcers in high-risk patients. Here, we investigated the protective effect of the natural product, stable gastric pentadecapeptide 157 (BPC 157) on Clopidogrel-induced gastric injury. We used acetic acid to induce gastric ulcer in Sprague Dawley rats. Clopidogrel alone or in combination with BPC 157 or L-NAME (nitric oxide system blockade) were administered after healing of acetic acid-induced ulcer. One perce…

  56. 102.

    Smoday IM, Petrovic I, Kalogjera L, Vranes H, et al. · Biomedicines · 2022 · PMID 35740321

    We revealed the therapy effect of the stable gastric pentadecapeptide BPC 157 (10 μg/kg, 10 ng/kg ig or po) with specific activation of the collateral rescuing pathways, the azygos vein, on bile duct ligation in particular, and acute pancreatitis as local disturbances (i.e., improved gross and microscopy presentation, decreased amylase level). Additionally, we revealed the therapy's effect on the acute pancreatitis as vascular failure and multiorgan failure, both peripherally and centrally follo…

  57. 103.

    Sever AZ, Sever M, Vidovic T, Lojo N, et al. · European journal of pharmacology · 2019 · PMID 30690000

    Recently, stable gastric pentadecapeptide BPC 157 reversed the high MDA- and NO-tissue values to the healthy levels. Thereby, BPC 157 therapy cured rats with bile duct ligation (BDL) (sacrifice at 2, 4, 6, 8 week). BPC 157-medication (10 μg/kg, 10 ng/kg) was continuously in drinking water (0.16 μg/ml, 0.16 ng/ml, 12 ml/rat/day) since awakening from surgery, or since week 4. Intraperitoneal administration was first at 30 min post-ligation, last at 24 h before sacrifice. Local bath BPC 157 (10 µg/…

  58. 104.

    Boban Blagaic A, Turcic P, Blagaic V, Dubovecak M, et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2009 · PMID 20388962

    Previously, the gastric pentadecapeptide BPC 157, (PL 14736, Pliva) has been shown to have several beneficial effects, it exert gastroprotective, anti-inflammatory actions, stimulates would healing and has therapeutic value in inflammatory bowel disease. The present study aimed to study the effect of naloxone and BPC 157 on morphine-induced antinociceptive action in hot plate test in the mouse. It was found that naloxone and BPC 157 counteracted the morphine (16 mg/kg s.c.) - analgesia. Naloxone…

  59. 105.

    Mirković I, Kralj T, Lozić M, Stambolija V, et al. · Acta clinica Croatica · 2020 · PMID 34177048

    We focused on the relationship of 0.5% tetracaine- and 0.4% oxybuprocaine-induced corneal anesthesia in rats, and pentadecapeptide BPC 157 (0.4 µg/eye), along with nitric oxide synthase (NOS) inhibitor N(gamma)-nitro-L-arginine methyl ester (L-NAME) (0.1 mg/eye) and/or NOS substrate L-arginine (2 mg/eye), applied in the form of eye drops. We assessed corneal sensitivity recovery (Cochet-Bonnet esthesiometer), corneal lesion elimination (staining with 10% fluorescein) and decrease in tear volume…

  60. 106.

    Masnec S, Kokot A, Zlatar M, Kalauz M, et al. · Experimental eye research · 2015 · PMID 25912999

    Based on its healing effects in various tissues, we hypothesized that the stable gastric pentadecapeptide BPC 157 heals corneal ulcerations in rats and effects corneal transparency. We made a penetrant linear 2-mm incision in the paralimbal region of the left cornea at the 5 o'clock position with a 20-gauge MVR incision knife at 45° under an operating microscope. Medication was BPC 157 (2 pg/mL, 2 ng/mL, and 2 μg/mL distilled water, two eye drops/left rat eye) immediately after injury induction…

  61. 107.

    Sikirić P, Mazul B, Seiwerth S, Grabarević Z, et al. · Digestive diseases and sciences · 1997 · PMID 9073154

    Since superior protection against different gastrointestinal and liver lesions and antiinflammatory and analgesic activities were noted for pentadecapeptide BPC (an essential fragment of an organoprotective gastric juice protein named BPC), the beneficial mechanism of BPC 157 and its likely interactions with other systems were studied. Hence its beneficial effects would be abolished by adrenal gland medullectomy, the influence of different agents affecting alpha, beta, and dopamine receptors on…

  62. 108.

    Cox HD, Miller GD, Eichner D · Drug testing and analysis · 2017 · PMID 28035768

    A new peptide, body protecting compound (BPC), BPC 157, and a variant of mechano-growth factor (MGF), MGF R23H, were identified in confiscated vials. BPC 157 has the amino acid sequence, GEPPPGKPADDAGLV, and is currently under investigation for the promotion of healing and recovery in a variety of tissues. In vitro metabolism experiments in plasma demonstrate that MGF R23H has good stability and should be detectable in urine, while BPC 157 forms a stable metabolite that should be detectable in u…

  63. 109.

    Rasic D, Zenko Sever A, Rasic F, Strbe S, et al. · Biomedicines · 2021 · PMID 34572392

    With the stable gastric pentadecapeptide BPC 157 therapy known to heal various both external and internal rat fistulas, we attempt to approach vesicovaginal fistula, continuous urine leaking through vagina, bladder stones, and a possible therapy solution among rats with well-formed 2 week-fistulas (vaginal/vesical 4 mm large defects) started with delayed therapy. Subsequent control fistula course (the subsequent 1, 2, 4, and 6 weeks) since beginning revealed the failed healing, fistula leaking,…

  64. 110.

    Drmic D, Samara M, Vidovic T, Malekinusic D, et al. · World journal of gastroenterology · 2018 · PMID 30622376

    To study the counteraction of perforated cecum lesion using BPC 157 and nitric oxide (NO) system agents. Alongside with the agents' application (after 1 min, medication (/kg, 10 mL/2 min bath/rat) includes: BPC 157 (10 μg), L-NAME (5 mg), L-arginine (100mg) alone or combined, and saline baths (controls)) on the rat perforate cecum injury, we continuously assessed the gross reappearance of the vessels (USB microcamera) quickly propagating toward the defect at the cecum surface, defect contraction…

  65. 111.

    Xue XC, Wu YJ, Gao MT, Li WG, et al. · World journal of gastroenterology · 2004 · PMID 15052688

    To investigate the protective effects of gastric pentadecapeptide BPC 157 on acute and chronic gastric ulcers in rats and to compare the results in therapy of human gastric ulcers by different administration methods. Gastric pentadecapeptide BPC 157 was administered (initial single or continuous administration) into rats either intragastrically or intramuscularly before (induced acute gastric ulcer) or after (induced chronic gastric ulcer) the applications of inducing agents, and each animal was…

  66. 112.

    Klicek R, Sever M, Radic B, Drmic D, et al. · Journal of pharmacological sciences · 2008 · PMID 18818478

    We focused on the therapeutic effect of the stable gastric pentadecapeptide BPC 157 and how its action is related to nitric oxide (NO) in persistent colocutaneous fistula in rats (at 5 cm from anus, colon defect of 5 mm, skin defect of 5 mm); this peptide has been shown to be safe in clinical trials for inflammatory bowel disease (PL14736) and safe for intestinal anstomosis therapy. BPC 157 (10 microg/kg, 10 ng/kg) was applied i) in drinking water until the animals were sacrificed at post-operat…

  67. 113.

    Gojkovic S, Krezic I, Vrdoljak B, Malekinusic D, et al. · World journal of gastrointestinal pathophysiology · 2020 · PMID 32226643

    Recently, as a possible therapy resolving solution, pentadecapeptide BPC 157 therapy, has been used in alleviating various vascular occlusion disturbances. BPC 157 was previously reviewed as novel mediator of Robert cytoprotection and endothelium protection in the stomach, and gut-brain axis, beneficial therapy in gastrointestinal tract, with particular reference to vascular recruitment, ulcerative colitis and tumor cachexia, and other tissues healing. Here we raised new hypothesis about BPC 157…

  68. 114.

    Strbe S, Gojkovic S, Krezic I, Zizek H, et al. · Biomedicines · 2021 · PMID 34829735

    Due to endothelial impairment, high-dose lithium may produce an occlusive-like syndrome, comparable to permanent occlusion of major vessel-induced syndromes in rats; intracranial, portal, and caval hypertension, and aortal hypotension; multi-organ dysfunction syndrome; brain, heart, lung, liver, kidney, and gastrointestinal lesions; arterial and venous thrombosis; and tissue oxidative stress. Stable gastric pentadecapeptide BPC 157 may be a means of therapy via activating loops (bypassing vessel…

  69. 115.

    Japjec M, Horvat Pavlov K, Petrovic A, Staresinic M, et al. · Biomedicines · 2021 · PMID 34829776

    (1) Aim: The stable gastric pentadecapeptide BPC 157 is known to heal transected muscle, tendon, and ligament. Thereby, in this study, we investigated the effect of BPC 157 on the dissection of the quadriceps tendon from the quadriceps muscle in rats. (2) Materials and Methods: Myotendinous junction defect, which cannot heal spontaneously in rats, as evidenced with consistent macro/microscopic, biomechanical, functional assessments,

  70. 116.

    Udovicic M, Sever M, Kavur L, Loncaric K, et al. · Biomedicines · 2021 · PMID 34356886

  71. 117.

    Perovic D, Milavic M, Dokuzovic S, Krezic I, et al. · Current issues in molecular biology · 2022 · PMID 35678659

    Recently, marked therapeutic effects pertaining to the recovery of injured rat spinal cords (1 min compression injury of the sacrocaudal spinal cord (S2-Co1) resulting in tail paralysis) appeared after a single intraperitoneal administration of the stable gastric pentadecapeptide BPC 157 at 10 min post-injury. Besides the demonstrated rapid and sustained recovery (1 year), we showed the particular points of the immediate effect of the BPC 157 therapy that began rapidly after its administration,…

  72. 118.

    DiStefano MJ, Dardouri M, Moore GD, Saseen JJ, et al. · Journal of pharmaceutical policy and practice · 2025 · PMID 39776466

    High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot study to assess the prevalence, characteristics, and advertising content of direct-to-consumer providers of compounded glucagon-like peptide-1 products for weight loss in Colorado. We conducted a cross-sectional study of websites advertising compounded glu…

  73. 119.

    Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2003 · PMID 14554208

    In studies intended to improve healing of transected Achilles tendon, effective was a stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419). Currently in clinical trials for inflammatory bowel disease (PLD-116, PL 14736, Pliva), it ameliorates internal and external wound healing. In rats, the right Achilles tendon transected (5 mm proximal to its calcaneal insertion) presents with a large tendon defect between cut ends. Agents (/kg b.w., i.p., once time daily) (BPC 157 (dissolved…

  74. 120.

    Sikiric P, Jadrijevic S, Seiwerth S, Sosa T, et al. · Journal of physiology, Paris · 1999 · PMID 10672991

    Recently, the effectiveness of pentadecapeptide BPC 157 and other anti-ulcer agents, called 'direct cytoprotection', was evidenced in totally gastrectomized rats duodenum challenged with cysteamine 24 h after surgery, and sacrificed 24 h after ulcerogen application. The further focus was on the possibility that this effect could be seen over a more prolonged period (1, 2, 4 weeks), and in other parts of the gastrointestinal tract (i.e. oesophagus). After the removal of the stomach, the oesophagu…

  75. 121.

    Sikirić P, Seiwerth S, Grabarević Z, Rucman R, et al. · European journal of pharmacology · 1997 · PMID 9298922

    The known effects of a novel stomach pentadecapeptide BPC157 (10 microg or 10 ng/kg), namely its salutary activity against ethanol (96%, i.g.)-induced gastric lesions (simultaneously applied i.p.) and in blood pressure maintenance (given i.v.), were investigated in rats challenged with a combination of N(G)-nitro-L-arginine methylester (L-NAME) (5 mg/kg i.v.), a competitive inhibitor of endothelium nitric oxide (NO)-generation and NO precursor, L-arginine (200 mg/kg i.v.) (D-arginine was ineffec…

  76. 122.

    Blagaic AB, Blagaic V, Romic Z, Sikiric P · European journal of pharmacology · 2004 · PMID 15381050

    The stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W.1419), which was promising in inflammatory bowel disease (PL-10, PLD-116, PL-14736, Pliva) trials, protects against both acute and chronic alcohol-induced lesions in stomach and liver, but also, given peripherally, affects various centrally mediated disturbances. Now, in male NMRI mice BPC 157 (10 pg intraperitoneally, 10 ng and 10 microg, intraperitoneally or intragastrically) (i) strongly opposed acute alcohol (4 g/kg intraperit…

  77. 123.

    Drmic D, Kolenc D, Ilic S, Bauk L, et al. · World journal of gastroenterology · 2017 · PMID 28839430

    To counteract/reveal celecoxib-induced toxicity and NO system involvement. Celecoxib (1 g/kg b.w. ip) was combined with therapy with stable gastric pentadecapeptide BPC 157 (known to inhibit these lesions, 10 μg/kg, 10 ng/kg, or 1 ng/kg ip) and L-arginine (100 mg/kg ip), as well as NOS blockade [N(G)-nitro-L-arginine methyl ester (L-NAME)] (5 mg/kg ip) given alone and/or combined immediately after celecoxib. Gastrointestinal, liver, and brain lesions and liver enzyme serum values in rats were as…

  78. 124.

    Zemba M, Cilic AZ, Balenovic I, Cilic M, et al. · Inflammopharmacology · 2015 · PMID 26563892

    We hypothesized that certain effects of the general anaesthetic thiopental are dependent on NO-related mechanisms, which were consequently counteracted by stable gastric pentadecapeptide BPC 157. (1) All rats intraperitoneally received thiopental (20, 30, 40, and 50 mg/kg) while medication BPC 157 (10 μg/kg, 10 ng/kg, and 10 pg/kg) was given intraperitoneally at 5 min before thiopental. (2) To determine NO-related mechanisms, all rats received intraperitoneally thiopental 40 mg/kg while BPC 157…

  79. 125.

    Jandric I, Vrcic H, Jandric Balen M, Kolenc D, et al. · Medical science monitor basic research · 2013 · PMID 23478678

    Since an originally anti-ulcer stable gastric pentadecapeptide BPC 157 (PL 14736) was shown to promote healing of injured striated muscle and smooth muscle in the gastrointestinal tract, we explored its therapeutic potentials for leak point pressure (LPP) recovery in rat stress urinary incontinence (SUI) after transabdominal urethrolysis (TU) and prolonged vaginal dilatation (VD). During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/k…

  80. 126.

    Sever M, Klicek R, Radic B, Brcic L, et al. · Digestive diseases and sciences · 2009 · PMID 19093208

    The gastric pentadecapeptide BPC 157, which was shown to be safe as an antiulcer peptide in trials for inflammatory bowel disease (PL14736, Pliva), successfully healed intestinal anastomosis and fistula in rat. Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus. BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12…

  81. 127.

    Mikus D, Sikiric P, Seiwerth S, Petricevic A, et al. · Burns : journal of the International Society for Burn Injuries · 2001 · PMID 11718984

    The effects of the gastric pentadecapeptide BPC 157 were investigated when administered topically or systemically in burned mice. This agent is known to have a beneficial effect in a variety of models of gastrointestinal lesions, as well as on wound or fracture healing. Deep partial skin thickness burns (1.5x1.5 cm) covering 20% of total body area, were induced under anesthesia on the back of mice by controlled burning and gastric lesions were assessed 1, 2, 3, 7, 14 and 21 days following injury…

  82. 128.

    Stupnisek M, Kokot A, Drmic D, Hrelec Patrlj M, et al. · PloS one · 2015 · PMID 25897838

    BPC 157 is a stable gastric pentadecapeptide recently implicated with a role in hemostasis. While NO is largely implicated in hemostatic mechanisms, in tail-amputation-models under heparin- and warfarin-administration, both the NO-synthase (NOS)-blocker, L-NAME (prothrombotic) and the NOS-substrate L-arginine (antithrombotic), were little investigated. Objective. To investigate the effect of L-NAME and L-arginine on hemostatic parameters, and to reveal the effects of BPC 157 on the L-NAME- and L…

  83. 129.

    Kokot A, Zlatar M, Stupnisek M, Drmic D, et al. · European journal of pharmacology · 2016 · PMID 26698393

    We revealed an immediate and hours-lasting particular NO-specific parallel miotic effect of L-NAME and L-arginine in rats and guinea pigs and a stable gastric pentadecapeptide BPC 157 157-particular effect vs. that of atropine-induced mydriasis while examining the NO system role in the normal pupils responses and pupils with atropine-induced mydriasis. We also assessed the responses to BPC 157 and its possible modulation of the changes caused by L-NAME/L-arginine and atropine. We administered lo…

  84. 130.

    Sebecić B, Nikolić V, Sikirić P, Seiwerth S, et al. · Bone · 1999 · PMID 10071911

    Gastrectomy often results in increased likelihood of osteoporosis, metabolic aberration, and risk of fracture, and there is a need for a gastric peptide with osteogenic activity. A novel stomach pentadecapeptide, BPC-157, improves wound and fracture healing in rats in addition to having an angiogenic effect. Therefore, in the present study, using a segmental osteoperiosteal bone defect (0.8 cm, in the middle of the left radius) that remained incompletely healed in all control rabbits for 6 weeks…

  85. 131.

    Bedekovic V, Mise S, Anic T, Staresinic M, et al. · European journal of pharmacology · 2003 · PMID 14512101

    The focus was on salivary glands in cysteamine-induced duodenal ulcer and the different effects of antiulcer agents on cysteamine-induced duodenal ulcer in sialoadenectomized but not gastrectomized rats. We tested antiulcer agents on cysteamine-induced duodenal ulcer in rats (agents/kg i.p.) simultaneously with cysteamine 400 mg/kg s.c., rat killed 24 h thereafter subjected to no surgery (normal), to gastrectomy (24 h before) or sialoadenectomy, acute (24 h before) or chronic (21 days before). (…

  86. 132.

    Grubisic MM, Strbe S, Barisic I, Balenovic D, et al. · Current neuropharmacology · 2026 · PMID 41832718

    This review explores the therapeutic potential of the stable gastric pentadecapeptide BPC 157 in addressing electrolyte imbalances, specifically hyperkalemia, hypokalemia, hypermagnesemia, and hyperlithiemia. In hyperkalemia, BPC 157 demonstrated a comprehensive counteractive effect against KCl overdose (intraperitoneally, intragastrically, and in vitro), effectively mitigating symptoms such as muscular weakness, hypertension, sphincter dysfunction, arrhythmias, and lethality. It also counteract…

  87. 133.

    Strbe S, Smoday IM, Krezic I, Kalogjera L, et al. · Pharmaceuticals (Basel, Switzerland) · 2023 · PMID 37375736

    Even before behavioral disturbances, neuroleptics, amphetamine, and domperidone application rapidly emerged severe occlusion/occlusion-like syndrome, shared innate vascular and multiorgan failure in rats, comparable to occlusion/occlusion-like syndrome described with vessel(s) occlusion or similar noxious procedures application. As therapy, i.e., activation of the collateral pathways, "bypassing key" (activated azygos vein pathway, direct blood flow delivery), the stable gastric pentadecapeptide…

  88. 134.

    Sikiric P · Inflammopharmacology · 1999 · PMID 17657443

    The reported beneficial effects of the gastric mucosal derived pentadecapeptide BPC 157 (Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Asp Ala Gly Leu Val, M.W. 1419) on different organ lesions are reviewed. Apart from the effects on various gastrointestinal lesions, the potentially beneficial effect on pancreas, liver injuries, endothelium and heart damage, i.e. dysrhythmias following reoxygenation, and blood pressure, along with effect on experimental acute/chronic inflammation, wound and fracture (…

  89. 135.

    Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, et al. · Journal of physiology, Paris · 1997 · PMID 9403784

    Besides a superior protection of the pentadecapeptide BPC 157 (an essential fragment of an organoprotective gastric juice peptide BPC) against different gastrointestinal and liver lesions, an acute anti-inflammatory and analgetic activity was also noted. Consequently, its effect on chronic inflammation lesions, such as adjuvant arthritis, and non-steroidal anti-inflammatory agents (NSAIAs)-induced gastrointestinal lesions was simultaneously studied in rats. In gastrointestinal lesions (indometha…

  90. 136.

    Tlak Gajger I, Smodiš Škerl MI, Šoštarić P, Šuran J, et al. · Biology · 2021 · PMID 34571768

    Various factors contribute to a decline in diversity and number of bees. Here, an integrated approach in experimental BPC 157 therapy was implemented, combining laboratory-controlled and field study results. The aim of a study was to assess the effects of BPC 157 additional feeding of newly emerged worker honeybees on few biochemical and immunological parameters in hemolymph (glucose, trehalose, lipids, proteins, vitellogenin, glucose-oxidase (GOX)), and hypopharyngeal gland (HPG), in laboratory…

  91. 137.

    Yildirim AK, Dastan AO, Demeli Ertus M, Ensarioglu M, et al. · Journal of clinical medicine · 2026 · PMID 42123221

  92. 138.

    Perovic D, Kolenc D, Bilic V, Somun N, et al. · Journal of orthopaedic surgery and research · 2019 · PMID 31266512

    We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model. BPC 157, of which the LD1 has not been achieved, has been implemented as an anti-ulcer peptide in inflammatory bowel disease trials and recently in a multiple sclerosis trial. In animals, BPC 157 has an anti-inflammatory effect and therapeutic effects in functional recovery and the rescue of somatosensory neurons in the sciatic nerve after transection, upon brain injury a…

  93. 139.

    Strinic D, Belosic Halle Z, Luetic K, Nedic A, et al. · Life sciences · 2017 · PMID 28797793

    Commonly, neuroleptics and prokinetics induce a prolonged QTc interval. In this study, stable gastric pentadecapeptide BPC 157 counteracts the prolongation of the QTc interval in Wistar rats that underwent daily administration of dopamine neuroleptics or prokinetics. Previously, in rats and mice, BPC 157 counteracted neuroleptic-induced catalepsy and gastric ulcers. To counteract neuroleptic- or prokinetic-induced prolongation of the QTc interval, rats were given a BPC 157 regimen once daily ove…

  94. 140.

    Škrlec K, Ručman R, Jarc E, Sikirić P, et al. · Applied microbiology and biotechnology · 2018 · PMID 30191288

    Lactic acid bacteria (LAB) are attractive hosts for the expression of heterologous proteins and can be engineered to deliver therapeutic proteins or peptides to mucosal surfaces. The gastric stable pentadecapeptide BPC-157 is able to prevent and treat gastrointestinal inflammation by reducing the production of reactive oxygen species (ROS). In this study, we used LAB Lactococcus lactis as a vector to deliver BPC-157 by surface display and trypsin shedding or by secretion to the growth medium. Su…

  95. 141.

    Sucic M, Luetic K, Jandric I, Drmic D, et al. · European journal of pharmacology · 2019 · PMID 31401154

    We focused on the cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally throughout three days) as a particular NO-system disturbance, and therapy possibilities. We demonstrated that it may be attenuated by subsequent administration of the NOS substrate L-arginine (100 mg/kg/day intraperitoneally), aggravated by NOS-blocker L-NAME (5 mg/kg/day intraperitoneally), all influenced by the stable gastric pentadecapeptide BPC 157 (10 μg/kg/day, 10 ng/kg/day, intraperitoneally o…

  96. 142.

    Duzel A, Vlainic J, Antunovic M, Malekinusic D, et al. · World journal of gastroenterology · 2017 · PMID 29358856

    To provide new insights in treatment of colitis and ischemia and reperfusion in rats using stable gastric pentadecapeptide BPC 157. Medication [BPC 157, L-NAME, L-arginine (alone/combined), saline] was bath at the blood deprived colon segment. During reperfusion, medication was BPC 157 or saline. We recorded (USB microscope camera) vessel presentation through next 15 min of ischemic colitis (IC-rats) or reperfusion (removed ligations) (IC + RL-rats); oxidative stress as MDA (increased (IC- and I…

  97. 143.

    Djakovic Z, Djakovic I, Cesarec V, Madzarac G, et al. · World journal of gastroenterology · 2016 · PMID 27895400

    To cure typically life-threatening esophagogastric anastomosis in rats, lacking anastomosis healing and sphincter function rescue, in particular. Because we assume esophagogastric fistulas represent a particular NO-system disability, we attempt to identify the benefits of anti-ulcer stable gastric pentadecapeptide BPC 157, which was in trials for ulcerative colitis and currently for multiple sclerosis, in rats with esophagocutaneous fistulas. Previously, BPC 157 therapies have promoted the heali…

  98. 144.

    Tian T, Jing J, Li Y, Wang Y, et al. · Molecules (Basel, Switzerland) · 2023 · PMID 37959764

    Traditional strategies for the metabolic profiling of doping are limited by the unpredictable metabolic pathways and the numerous proportions of background and chemical noise that lead to inadequate metabolism knowledge, thereby affecting the selection of optimal detection targets. Thus, a stable isotope labeling-based nontargeted strategy combined with ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS) was first proposed for the effective and rapid metab…

  99. 145.

    Tepes M, Gojkovic S, Krezic I, Zizek H, et al. · Frontiers in pharmacology · 2021 · PMID 35126157

    [This corrects the article DOI: 10.3389/fphar.2021.718147.].

  100. 146.

    Balenovic D, Bencic ML, Udovicic M, Simonji K, et al. · Regulatory peptides · 2009 · PMID 19465062

    Pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419) reversed congestive heart failure and various arrhythmias, influenced the NO-system and showed no proarrhythmic effect. In therapy analogy, we challenged rats with digitalis, to show attenuation by BPC 157 and the relation between the NO-system and digitalis toxicity. (i). BPC 157 prophylactic effect. Development of cumulative intravenous digitalis toxicity, BPC 157 (50 microg, 10 microg, 10 ng/kg applied intravenously immediately before a meth…

  101. 147.

    Tlak Gajger I, Ribarić J, Smodiš Škerl M, Vlainić J, et al. · Journal of veterinary pharmacology and therapeutics · 2018 · PMID 29682749

    Nosema ceranae can cause major problems, such as immune suppression, gut epithelial cell degeneration, reduced honeybee lifespan, or suddenly colony collapse. As a novel approach in therapy, we hypothesize the stable gastric pentadecapeptide BPC 157 in honeybee therapy, to control N. ceranae invasions in apiary conditions: BPC 157 treated sugar syrup (0.25 L sugar syrup supplemented with 0.1 μg/ml BPC 157), as well as the pure sugar syrup (0.25 L sugar syrup; control), was administered to honeyb…

  102. 148.

    Medvidovic-Grubisic M, Stambolija V, Kolenc D, Katancic J, et al. · Inflammopharmacology · 2017 · PMID 28210905

    Stable gastric pentadecapeptide BPC 157, administered before a high-dose magnesium injection in rats, might be a useful peptide therapy against magnesium toxicity and the magnesium-induced effect on cell depolarization. Moreover, this might be an NO-system-related effect. Previously, BPC 157 counteracts paralysis, arrhythmias and hyperkalaemia, extreme muscle weakness; parasympathetic and neuromuscular blockade; injured muscle healing and interacts with the NOS-blocker and NOS-substrate effects.…

  103. 149.

    Tudor M, Jandric I, Marovic A, Gjurasin M, et al. · Regulatory peptides · 2010 · PMID 19931318

    Gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, an anti-ulcer peptide, efficient in inflammatory bowel disease trials (PL 14736), no toxicity reported, improved muscle crush injury. After an induced traumatic brain injury (TBI) in mice by a falling weight, BPC 157 regimens (10.0microg, 10.0ng/kgi.p.) demonstrated a marked attenuation of damage with an improved early outcome and a minimal postponed mortality throughout a 24h post-injury period. Ultimately, the traumatic lesions (subarachnoidal…

  104. 150.

    Grabarevic Z, Tisljar M, Artukovic B, Bratulic M, et al. · Journal of physiology, Paris · 1997 · PMID 9403788

    We describe the effects of nitric oxide (NO) agonists and antagonists and the influence of a novel organoprotective pentadecapeptide BPC 157, on the development of pulmonary hypertension syndrome and tissue lesions in chicks. Acute toxicity, which includes single dose application of saline (1 mL intraperitoneally (i.p.)), BPC 157 (10 micrograms/kg bw), L-NAME (NO antagonist, doses 50, 100, 150 mg/kg bw) and L-arginine (NO agonist/100 mg/kg bw with their combination L-NAME + BPC 157; L-NAME + L-a…

  105. 151.

    Ilic S, Drmic D, Franjic S, Kolenc D, et al. · Life sciences · 2011 · PMID 21295044

    We attempted to fully antagonize the extensive toxicity caused by NSAIDs (using diclofenac as a prototype). Herein, we used the stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419), an anti-ulcer peptide shown to be efficient in inflammatory bowel disease clinical trials (PL 14736) and various wound treatments with no toxicity reported. This peptide was given to antagonize combined gastrointestinal, liver, and brain toxicity induced by diclofenac (12.5mg/kg intraperitoneally, once…

  106. 152.

    Krivic A, Anic T, Seiwerth S, Huljev D, et al. · Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2006 · PMID 16583442

    Stable gastric pentadecapeptide BPC 157 (BPC 157, as an antiulcer agent in clinical trials for inflammatory bowel disease; PLD-116, PL 14736, Pliva, no toxicity reported) alone (without carrier) ameliorates healing of tendon and bone, respectively, as well as other tissues. Thereby, we focus on Achilles tendon-to-bone healing: tendon to bone could not be healed spontaneously, but it was recovered by this peptide. After the rat's Achilles tendon was sharply transected from calcaneal bone, agents…

  107. 153.

    Skorjanec S, Kokot A, Drmic D, Radic B, et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2015 · PMID 26348082

    While very rarely reported, duodenocutanenous fistula research might alter the duodenal ulcer disease background and therapy. Our research focused on rat duodenocutaneous fistulas, therapy, stable gastric pentadecapeptide BPC 157, an anti-ulcer peptide that healed other fistulas, nitric oxide synthase-substrate L-arginine, and nitric oxide synthase-inhibitor L-nitro-arginine methyl ester (L-NAME). The hypothesis was, duodenal ulcer-healing, like the skin ulcer, using the successful BPC 157, with…

  108. 154.

    Lazić R, Gabrić N, Dekaris I, Bosnar D, et al. · Collegium antropologicum · 2005 · PMID 16117343

    We evaluated the role of human gastric pentadecapeptide BPC 157 in corneal epithelial defects healing in rats. 48 rats, in 4 groups (N=12). Total debridement of corneal epithelium preformed unilaterally and lesions stained and photographed. Animals medicated as follows: distilled water (control group) or BPC 157 2 pg/ml, 2 ng/ml, 2 microg/ml, 2 drops/rat eye started immediately after injury induction, every 8 hours up to 40 hours (i.e., at 0, 8, 16, 24, 32, 40 h). Lesions were photographed befor…

  109. 155.

    Cesar LB, Gojkovic S, Krezic I, Malekinusic D, et al. · World journal of gastrointestinal pharmacology and therapeutics · 2020 · PMID 33251034

    After parietal peritoneum excision with an underlying superficial layer of muscle tissue in rats, there is failed vasculature, and finally, increased adhesion formation. We hypothesized that unlike nitric oxide (NO)-agents, L-NAME and/or L-arginine, the application of the stable gastric pentadecapeptide BPC 157 with its most recent vascular effects ("vascular recruitment") means attenuated bowel adhesion formation and NO- and malondialdehyde (MDA)-tissue values. To focused on the bowel adhesion…

  110. 156.

    Sikiric P, Seiwerth S, Mise S, Staresinic M, et al. · Burns : journal of the International Society for Burn Injuries · 2003 · PMID 12781609

    The amelioration of corticosteroid-impairment of healing by a stable gastric pentadecapeptide BPC-157 (GEPPPGKPADDAGLV, M(w) 1419, currently in early clinical trials for inflammatory bowel disease) was studied in thermally injured mice. Its effects on corticosteroid impaired healing of deep partial skin thickness burns, and burn-gastric lesions were investigated. Male NMRI-Hannover mice (sacrificed at 1-3,7,14 and 21 days following burning 20% of total burn area at the back (open flame for 7s) r…

  111. 157.

    Novinscak T, Brcic L, Staresinic M, Jukic I, et al. · Surgery today · 2008 · PMID 18668315

    Stable gastric pentadecapeptide BPC 157 accelerates the healing of a transected Achilles tendon and a transected quadriceps muscle. It may also be of clinical relevance as a systemic and local peptide treatment for crush injury of a major muscle, such as gastrocnemius muscle complex. BPC 157 is effective without a carrier, and it is presently undergoing trials for inflammatory bowel disease, and no toxicity has so far been reported. In crushed rats (force delivered 0.727 Ns/cm2), BPC 157 was app…

  112. 158.

    Sikiric P, Barisic I, Udovicic M, Lovric Bencic M, Balenovic D, Strinic D, Posilovic GZ, Uzun S, Vranes H, Krezic I, Lozic M, Stambolija V, Premuzic Mestrovic I, Oreskovic LB, Kalogjera L, Strbe S, Sikiric S, Tomic L, Stupnisek M, Kordic M, Tvrdeic A, Seiwerth S, Boban Blagaic A, Skrtic A. · 2026 · PMID 41901308

    This review presents an innovative and timely exploration of how cytoprotection can serve as a cohesive therapeutic approach by which to address the hemorrhage-thrombosis paradox. Presenting counteraction of both hemorrhage and thrombosis as phase-dependent outcomes of vascular dysregulation, the manuscript synthesizes conceptual, experimental, and clinical evidence into a unified systems-level model focused on the stable gastric pentadecapeptide BPC 157, which acts as a cytoprotective mediator.…

  113. 159.

    Sikiric P, Barisic I, Udovicic M, Lovric Bencic M, Balenovic D, Strinic D, Zivanovic Posilovic G, Uzun S, Vranes H, Krezic I, Lozic M, Stambolija V, Premuzic Mestrovic I, Beketic Oreskovic L, Oreskovic I, Strbe S, Sikiric S, Tomic L, Kordic M, Tvrdeic A, Seiwerth S, Boban Blagaic A, Skrtic A. · 2026

  114. 160.

    Matek D, Matek I, Japjec M, Matek M, Prenc J, Staresinic B, Staresinic E, Prtoric A, Sikiric S, Beketic Oreskovic L, Oreskovic I, Strbe S, Kordic M, Tvrdeic A, Seiwerth S, Sikiric P, Boban Blagaic A, Skrtic A, Bojanic I, Dobric I, Staresinic M. · 2026

  115. 161.

    Matek D, Matek I, Japjec M, Matek M, Prenc J, Staresinic B, Staresinic E, Prtoric A, Sikiric S, Beketic Oreskovic L, Oreskovic I, Strbe S, Kordic M, Tvrdeic A, Seiwerth S, Sikiric P, Boban Blagaic A, Skrtic A, Bojanic I, Dobric I, Staresinic M. · 2026 · PMID 41754849

    As a novel theoretical and practical advantage, preclinical to clinical evidence, this systematic review of PRP, growth factors, and stable gastric pentadecapeptide BPC 157 efficacy in complex musculoskeletal and junctional injuries emphasizes the cytoprotection concept, healing to restore tissue integrity. Notably, the concept holds tendon, ligament, and muscle healing, in particular. Then, it holds their healing together as interconnected lesions. Consequently, this review presents the possibi…

  116. 162.

    Smoday IM, Vukovic V, Oroz K, Vranes H, Kalogjera L, Gamulin O, Vlainic J, Milavic M, Sikiric S, Nikolac Gabaj N, Marijancevic D, Koprivanac A, Beketic Oreskovic L, Oreskovic I, Strbe S, Barisic I, Kordic M, Tvrdeic A, Seiwerth S, Sikiric P, Boban Blagaic A, Skrtic A. · 2026 · PMID 41599787

    <b>Background:</b> No Fourier transform infrared (FTIR) spectroscopy studies have directly evaluated adrenalectomy vessels, the technique's established ability to probe collagen/elastin-associated spectral features and lipid peroxidation-related signatures, and protein structural damage. Stable gastric pentadecapeptide BPC 157 therapy was found to maintain the vascular function under severe stress, as FTIR spectroscopy recently demonstrated rapid peptide-induced molecular changes in healthy rat…

  117. 163.

    Madzarac G, Becejac T, Penovic T, Drazenovic D, Kralj L, Popović Dolic M, Sikiric S, Beketic Oreskovic L, Oreskovic I, Strbe S, Tubikanec AM, Penavic M, Vranes H, Krezic I, Kordic M, Koprivanac A, Vidovic T, Vlainic J, Stancic Rokotov D, Boban Blagaic A, Seiwerth S, Skrtic A, Sikiric P. · 2026 · PMID 41599743

    <b>Background/Objectives:</b> This 7-day rat tracheocutaneous fistula study considered the not-studied issues of tracheocutaneous fistula course, wound healing, and fistula in the NO-system relations. Therefore, we focused on fistulas' severe course, tracheocutaneous fistula → air leak → compensatory diaphragmatic/abdominal "heaving", NO-system failed relations, and therapy resolution. Stable gastric pentadecapeptide BPC 157 was proposed. <b>Methods</b>: Tracheocutaneous fistula rats received da…

  118. 164.

    Sikiric P, Barisic I, Udovicic M, Lovric Bencic M, Balenovic D, Strinic D, Zivanovic Posilovic G, Uzun S, Vranes H, Krezic I, Lozic M, Stambolija V, Premuzic Mestrovic I, Beketic Oreskovic L, Oreskovic I, Strbe S, Sikiric S, Tomic L, Kordic M, Tvrdeic A, Seiwerth S, Boban Blagaic A, Skrtic A. · 2026 · PMID 41754776

    This review examines and hypothesizes cytoprotection as a conceptual therapeutic criterion for antiarrhythmic drugs, referring to the possibility of suppressing arrhythmias while avoiding adverse electrophysiological or systemic effects. Toward a theoretically complete cytoprotective profile-preserving benefits and eliminating toxicity-the criterion was the degree of counteraction of arrhythmias (i.e., bradycardia, tachycardia, atrioventricular (AV) block, ventricular tachycardia (VT), ST-segmen…

  119. 165.

    Rosenberg AE, Taylor B, Rasquinha RD, Khan H, Quinn M, Marcaccio S, Lemme N. · 2026 · PMID 41877514

  120. 166.

    Mavrych V, Shypilova I, Bolgova O. · 2026 · PMID 42021992

    <h4>Background</h4>Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.<h4>Objective</h4>To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions.<h4>Methods</h4>A comprehensiv…

  121. 167.

    Renke G, Chinellato L. · 2026 · PMID 42123471

    Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes. While several peptide drugs have undergone rigorous approval processes that evaluate both safety and efficacy, novel, unapproved compounds have emerged and are rapidly expanding into preventive medicine and performance enhancement. Our objective is to present the effects, clinical applications, safety profiles, and regulatory status of prominent peptides used…

  122. 168.

    Cushman CJ, Ibrahim AF, Smith AD, Hernandez EJ, MacKay B, Zumwalt M. · 2024 · PMID 39351323

    <b>Background</b>: The musculoskeletal system, due to inherent structure and function, lends itself to contributing toward joint pain, whether from inflammatory disorders such as rheumatoid arthritis, degenerative diseases such as osteoarthritis, or trauma causing soft tissue injury. Administration of peptides for treatment of joint pain or inflammation is an emerging line of therapy that seeks to offer therapeutic benefits while remaining safe and relatively non-invasive. <b>Purpose</b>: The pu…

  123. 169.

    Aabedi A, Agrawal DK. · 2026 · PMID 41852545

    Lumbar disc degeneration is a leading contributor to chronic low back pain and functional limitation worldwide, driven by progressive extracellular matrix breakdown, disc dehydration, inflammation, and cellular senescence. Conventional treatments-including pharmacotherapy, physical rehabilitation, and surgery-primarily address symptoms rather than the underlying degenerative cascade and often fail to restore disc structure or long-term mobility. Emerging biologic therapies have gained attention…

  124. 170.

    Zhang J, Liu M, Ou H, Wang Z, He L, Xiao Y, Xie F, Yu D, Cao H, He W, Wang S, Zhang W, Zhang K, Zhang Y, Li M, Hao Q. · 2026 · PMID 41606641

  125. 171.

    Kołodyńska K, Kamysz W, Kleczkowska P. · 2026 · PMID 41596336

    A wound has been defined as a disruption of tissue integrity. Pain, bleeding, and the risk of infection are inherent features of wounds, while chronic wounds are often accompanied by serous exudate. Pain associated with chronic wounds is usually underestimated and inadequately addressed in routine clinical care, despite being considered by patients as one of the most burdensome factors affecting their quality of life. Traditionally, management of wound-related pain has relied primarily on system…

  126. 172.

    Gamulin O, Oroz K, Coric L, Krajacic M, Skrabic M, Dretar V, Strbe S, Talapko J, Juzbasic M, Krezic I, Lozic M, Stambolija V, Zizek H, Jurca I, Jurjevic I, Blagaic AB, Skrtic A, Seiwerth S, Sikiric P. · 2022 · PMID 36551886

    Recently, it was found that when confronted with major vessel occlusion and vascular failure, stable gastric pentadecapeptide BPC 157 therapy might rapidly functionally improve minor vessels to take over the function of disabled major vessels, reorganize blood flow, and compensate failed vessel function. We focused on the BPC 157 therapy effect obtained by giving 10 ng/kg ip to rats 5 min before sacrifice on the rat thoracic aorta, which we assessed with Fourier transform infrared spectroscopy (…

  127. 173.

    Tham A, Hodgkins CW, Kennedy JG · The Journal of the American Academy of Orthopaedic Surgeons · 2026 · PMID 42937313

    Peptide-based products, particularly Body Protection Compound-157 (BPC-157), and thymosin beta-4 (TB-4), and products marketed as TB-500, are increasingly promoted for musculoskeletal recovery despite limited clinical validation. This narrative review evaluated their molecular rationale, direct musculoskeletal evidence, human safety and efficacy data, product quality concerns, regulatory status, antidoping implications, and relevance to orthopaedic counseling. PubMed/MEDLINE, EMBASE, and Scopus…

  128. 174.

    Tewari K, Liu TP, Im C, Hamad C, et al. · The American journal of sports medicine · 2026 · PMID 42578445

    The peptide supplement market has experienced rapid growth due to marketing claims of enhanced performance and accelerated recovery from musculoskeletal injury. These peptides are increasingly popular with patients and athletes and are often perceived as low risk, despite the absence of efficacy or safety data for many emerging peptides. To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide])…

  129. 175.

    Arunim, Dagar M, Solanki M, Sarita, et al. · 3 Biotech · 2026 · PMID 42555375

    Multifunctional hydrogels are essential for advanced biomedical applications. In this study, CH/BPC composite hydrogel was fabricated and characterized for their physicochemical properties. The formulation exhibited a porous structure, analyzed through scanning electron microscopy (SEM) and transmission electron microscopy (TEM). Fourier-transform infrared spectroscopy (FTIR) showed the presence of hydrogen bond between BPC-157 peptide and chitosan backbone, indicating successful peptide incorpo…

  130. 176.

    Biçer O, Adanir O, Güleryüz Y, Balci EC, et al. · Joint diseases and related surgery · 2026 · PMID 42542926

    This study aims to evaluate the effects of BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses in a rat model. Thirty-two male Sprague-Dawley rats, each aged 12 weeks and weighing approximately 330 g, underwent standardized Achilles tendon transection and repair and were randomly assigned to four groups, with eight rats in each group: control, BPC-157 (10 µg/kg/day),…

  131. 177.

    Vukoja I, Vlainic J, Francina M, Barisic I, et al. · Journal of physiology and pharmacology : an official journal of the Polish Physiological Society · 2026 · PMID 42533460

    In rats, stable gastric pentadecapeptide (BPC 157) therapy may resolve severe gentamicin nephrotoxicity (100 mg/kg ip/daily through 8 days) and the nitric oxide (NO)-system relation. We applied BPC 157 (10 µg/kg, 10 ng/kg, in drinking water or daily intraperitoneally) along with a triple NO-agent approach. Triple NO-agent approach captures NO-system, as a whole, simultaneously the inhibition (N(G)-nitro-L-arginine methylester (L-NAME) 5 mg/kg ip/daily), the overstimulation (L-arginine, 100 mg/kg…

  132. 178.

    Smoday IM, Vukovic V, Oroz K, Vranes H, et al. · Pharmaceuticals (Basel, Switzerland) · 2026 · PMID 42356491

  133. 179.

    Jelińska J, Józwiak M, Szeleszczuk Ł, Sikora K, et al. · International journal of molecular sciences · 2026 · PMID 42278509

    Acetylcholinesterase (AChE) inhibition remains a key therapeutic strategy in the management of neurodegenerative disorders such as Alzheimer's disease. In this study, the inhibitory potential of the gastric pentadecapeptide BPC-157 and two newly designed hybrid analogs, CIARA-1 and CIARA-2, was investigated for the first time. The hybrid peptides were rationally designed by combining a BPC-157-derived fragment with an arginine-containing C-terminal sequence to enhance interactions with the enzym…

  134. 180.

    Yıldırım AK, Demirtaş H, Özer A, Arslan M · Scientific reports · 2026 · PMID 42204242

    Ischemia-reperfusion (I/R) injury remains a major complication in peripheral arterial disease, characterized by oxidative stress, inflammation, and apoptosis. Body Protection Compound-157 (BPC 157), a stable gastric pentadecapeptide, has demonstrated cytoprotective properties in multiple tissues. This study aimed to evaluate the protective effects of BPC 157 in a rat model of lower limb I/R injury. Twenty-four male Wistar albino rats were randomized into four groups (n = 6): SHAM, B (BPC 157 onl…

Preprints (not yet peer-reviewed)

10
  1. 181.

    SCHLOSSER SK. · 2025

    <title>Abstract</title> <p> Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through…

  2. 182.

    SCHLOSSER SK. · 2025

    <title>Abstract</title> <p> Body Protection Compound-157 (BPC-157) is a synthetic pentadecapeptide derived from human gastric juice with regenerative and cytoprotective effects reported across diverse tissues. Despite extensive preclinical study, the precise molecular mechanism underlying BPC-157's pleiotropic pro-repair effects remains incompletely understood. A key unresolved question is whether BPC-157 acts through extracellular receptor engagement, via intracellular interactions, or through…

  3. 183.

    Mendias CL, Awan TM. · 2026

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

  4. 184.

    Mendias CL, Awan TM. · 2026

    Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration. The use of gray market peptides has grown substantially, with patients self-administering these compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement. The objective of this study was to evaluate the purity, measured abundance, and e…

  5. 185.

    Zhang H, Shao L, Feng Q, Guo Q, Wang H, Zhang H. · 2026

    <title>Abstract</title> <p>Stable expression of γ-Glutamyltranspeptidase (GGT)-BPC157 and mScarlet-BPC157 in Bacillus licheniformis strain 2709 by chromosomal integration. Fermentation conditions were optimized using single-factor and orthogonal experiments to maximize yield. Under optimal conditions (2% inoculum, 40g/L soybean peptone, and 80g/L glucose), target protein titers increased threefold compared to the basal medium. The fusion proteins were purified by fractional ammonium sulfate prec…

  6. 186.

    Mendias CL, Awan TM. · 2025

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

  7. 187.

    Majumdar P, Kaura S, Jafarova U, Matis G, Alam M, Lavrov I. · 2026

    Spinal cord injury (SCI) remains without an approved pharmacological therapy capable of restoring lost neurological function, and recovery in motor-complete, sensory-incomplete (AIS B) patients is constrained by a limited spontaneous-conversion profile. Two regenerative peptides have assembled convergent preclinical rationales in SCI. Thymosin β4 (Tβ4), the principal G-actin-sequestering peptide of eukaryotic cells, promotes oligodendrogenesis, axonal remodeling, angiogenesis, and anti-inflammat…

  8. 188.

    Cassinat J, Callan C, Liggett C, Wright V. · 2026

    <h4>Objective</h4> To describe how people use the unapproved peptides BPC-157 and TB-500 for tendon, ligament and muscle injury and what side effects they report. <h4>Methods</h4> Using a large language model validated against physician review, we analyzed 92,254 posts and comments from 28,652 users in Reddit’s peptide communities from 2021 to 2026. We compared side effects with those reported by users of four other peptides in the same communities. <h4>Results</h4> In all, 5,588 users described…

  9. 189.

    Koleng M, Joubran E, Alvi S, Thon VJF, Huynh BL, Garcia GDM, Menendez C, Nguyen JD, Onyeke SC, Shaker VA, Vo GN, Warlick H, Davis K, Gallicchio V, Rey J. · 2026

    <title>Abstract</title> <p> <bold>Introduction</bold> Chronic benzodiazepine (BZD) pharmacotherapy induces adaptive uncoupling between the GABA and benzodiazepine binding sites of the GABA-A receptor, contributing to tolerance, dependence, and withdrawal. <bold>Aim</bold> To synthesize mechanistic evidence on flumazenil's receptor-level reversal of this uncoupling and to evaluate Body Protection Compound-157 (BPC-157) as a mechanistically complementary agent addressing the downstream biologic co…

  10. 190.

    Venkatakrishnan A, Marwaha A, Gregg CJ, Varma G, Hurchik M, Murugadoss K, Shivabasappa S, Soundararajan V. · 2026

    Body Protection Compound-157 (BPC-157) is an unapproved synthetic peptide marketed directly to consumers despite limited human evidence on benefits and risks. We characterized the use of BPC-157 and patient-reported outcomes from 2020 through 2026 using Large Language Model (LLM) curation of de-identified clinical notes from a U.S. federated network with physician validation of each LLM-curation exercise. Of 1,536 patients with a note mentioning BPC-157, 1,039 (67.6%) had documented use, and qua…

Curated sources on file

9
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.

Continue reading